



Biofit

FOSTERING
INNOVATION
& TRANSFER

The leading European partnering event
for early-stage deals and investment
rounds in the Life Sciences field



BIOFIT AT A GLANCE

With the highest attending rate of academics, TTOs and research institutions, BioFIT is the place where **academia-industry collaborations** get started. BioFIT has taken on a whole new dimension becoming the meeting point in Europe for **tech transfer** and for sourcing **early-stage innovations** stemming from public research institutions, academic spin-offs and emerging biotech companies. Together with big pharma, biotech and diagnostic companies, BioFIT operates as a platform to **build partnerships for all public and private actors**. BioFIT is also the **European marketplace for pre-seed, seed and Series A investment in Life Sciences**.

BIOFIT 2019 KEY FIGURES:



1,300+
DELEGATES



35+
COUNTRIES REPRESENTED



10,000+
MEETINGS GENERATED



100+
EXHIBITORS



80+
SPEAKERS



50+
INNOVATION PITCHERS



WELCOME



Since its first edition, in 2010, BioFIT has become the leading European partnering event for early-stage deals and investment rounds in the Life Sciences field.

Today, we are very pleased to welcome you to Marseilles for the 8th edition of BioFIT, which has been developed, through the years, as the marketplace for pre-seed, seed and Series A investment in Life Sciences.

This edition will gather over 1,300 attendees from 35 countries, representing large companies, medium-sized businesses, start-ups as well as tech transfer organisations, academics and investors. Thanks to the quality and diversity of its participants, BioFIT looks certain to generate this year gain, excellent collaborating opportunities.

We wish you a fruitful and enjoyable two-day event, full of meeting and partnerships opportunities and we hope to see you next year in Strasbourg on December 1st and 2nd, 2020 for the 9th edition of BioFIT, where more meetings, deals and discoveries of early-stage innovations in Life Sciences!



Etienne Vervaecke
General Manager of **Eurasanté and Clubster-NHL**



Emilie Royere
General Manager of **Eurobiomed**



Marco Pintore
General Manager of **BioValley France**

Institutional Partners:



Organisers:



ORGANISERS



www.eurasante.com @Eurasante

Eurasanté is a technology transfer tool, an incubator, an accelerator and a cluster manager in the Health field in Northern France. Eurasanté assists French and foreign companies, entrepreneurs, scientists and clinicians with their innovation and development projects. The region includes over 1,000 healthcare companies with 30,800 employees in this sector. Eurasanté also promotes and develops the Eurasanté bio-business Park which hosts 7 hospitals, 4 universities, 7 specialised schools, 170 companies and 50 laboratories within a European-wide scientific and medical site. Eurasanté also organises four international healthcare-related partnering events that aim to increase and improve interaction between academia and industry: BioFIT (Life Sciences), MedFIT (MedTech, Diagnostic, Digital Health), NutrEvent (Food, Feed, Nutrition, Health) and AgeingFit (Healthy Ageing).



www.clubstersante.com @ClubsterNSL

Clubster-Nutrition Health Longevity (NHL) is a dynamic network at the intersection of health, biotechnology and nutrition. Clubster-NHL aims to connect academia and industry partners around R&D projects. It focuses on the prevention and treatment of lifestyle-related diseases, such as metabolic and cardiovascular pathologies, neurodegenerative diseases and inflammatory bowel diseases. Its goal is to bring together and support stakeholders from the health and food sectors in designing, developing and financing their future products and processes.



www.biovalley-france.com @BioValleyFrance

Competitiveness cluster since 2005, BioValley France aims to federate, develop and promote the healthcare sector in the Grand Est region through innovation. The cluster is based on a dynamic network of companies, a leading academic and clinical research, as well as an integrated network of key stakeholders in innovation. BioValley France supports its members in their R&D Innovation approach and gives them access to high value-added expertise, in a market approach. The Cluster contributes to the networking of the various actors and the creation of regional, national and international partnerships. Finally, BioValley France actively participates in the territory's structuring projects, such as Nextmed, which aims to create a Medical Technologies campus in Strasbourg that hosts an entire ecosystem of excellence dedicated to the development of tomorrow's health technologies.



www.eurobiomed.com @PoleEurobiomed

Founded in 2009 by regional stakeholders, EUROBIOMED is the Life Science cluster from Southern France. We gather more than 390 innovative biotech and medtech companies, as well as leading research institutes, hospitals and universities. We lead territorial initiatives and help our members businesses and research organisations to innovate, finance, develop and achieve their scientific and business objectives, to ultimately improve the treatment and the lives of patients.

Eurobiomed tops European rankings in all stages of innovation: education, basic, translational and clinical research, technological innovation centres, start-ups and industrial success stories. Some of Eurobiomed main assets are the number of people involved, but also the quality of the network and trust that is established between its members, which reinforces the interactions and facilitates collaborations.



Marseille One of the best innovative hubs for biotech in Europe

The Aix-Marseille-Provence Metropolis and the Sud Provence-Alpes-Côte d'Azur Region are a dynamic hotbed for biotech and pharma innovations, providing unrivalled assets and cutting-edge resources. This is due in particular to its leading research and training centres, its incubators which boost R&D projects, Eurobiomed, the cluster which supports innovations' development all along their development and its dedicated network including clusters, industries, SMEs and start-ups.

Life Science in Sud, Provence-Alpes-Côte d'Azur key numbers:

- **\$20 billion** Life Sciences GDP in the region
- **2nd largest French region** for clinical trials
- **170 laboratories** in the health research
- **39,000 science students** including 1,500 post-graduated with 8 universities and 4 teaching hospitals
- **41,000 life sciences entities**
- **169,400 employees**

RÉGION SUD

PROVENCE-ALPES-CÔTE D'AZUR

FRANCE

PRIORITY HEALTH



THIS IS THE LAND OF INNOVATIVE THERAPIES!

A **STRUCTURED, MULTI-SECTOR** NETWORK
FOSTERING MARKET OPPORTUNITIES AND INNOVATION

Markets

- Medication
- Medical devices
- E-Health
- Diagnostics

41 000 public and private players

3,38€ invested to date

#2 Région in France for patents
and clinical trials.


Specializations

- Immunotherapy
- Oncology
- Infections diseases
- Neurology
- Medical device



WIFI

Running out of battery?



Come to the on-site
registration desk
to borrow a
powerbank!



STEERING COMMITTEE

PHARMA, BIOTECH



Damien Chopy
X
ROCHE



Adrian Carter
CORPORATE VICE PRESIDENT
AND GLOBAL HEAD OF
DISCOVERY RESEARCH
COORDINATION,
BOEHRINGER INGELHEIM



Sami Chtourou
EXECUTIVE VICE PRESIDENT
INNOVATION & SCIENTIFIC
AFFAIRS, LFB



Florence Dal Degan
R&D INNOVATION SOURCING
DIRECTOR, NOVO NORDISK



Guy Hélin
CEO,
SYNGULON



Stephan Lensky
CHIEF OPERATING AND CHIEF
BUSINESS OFFICE,
EPIMAB BIOTHERAPEUTICS



Sabrina Lesage
STRATEGIC ALLIANCES
MANAGER,
PFIZER



Sara Nunez-Garcia
SENIOR DIRECTOR,
ROIVANT SCIENCES



Marie-Ange N'Zoutani
DIRECTOR, EXTERNAL
INNOVATION DRUG
DISCOVERY, BUSINESS
DEVELOPMENT & LICENSING,
SANOFI



Frédéric Scaërou
SENIOR DIRECTOR, HEAD
OF EXTERNAL INNOVATION
EUROPE AND ASIA,
IPSEN INNOVATION



Joachim Vogt
DIRECTOR, SEARCH AND
EVALUATION, WESTERN
EUROPE, ABBVIE



Nadine Weisslinger-Darmon
MEDICAL DIRECTOR
SPECIALTY PRODUCTS,
CLINICAL RESEARCH AND
ACADEMIC ALLIANCES, GSK

ACADEMIA, TTOS



Hervé Ansanay
OPERATIONS DIRECTOR,
SATT AXLR



Jürgen Bauer
DEPUTY MANAGING
DIRECTOR, EMBLEM
TECHNOLOGY TRANSFER



Garold Breit
CEO,
BREIT IDEAS LLP



Jean-Luc Chagnaud
HEALTHCARE BUSINESS
DEVELOPMENT MANAGER &
INTELLECTUAL PROPERTY
MANAGER, AQUITAINE
SCIENCE TRANSFERT



Anthony Daccache
BUSINESS DEVELOPER,
SATT NORD



Caroline Dreyer
PRESIDENT,
SATT CONECTUS



Lilla Farkas
HEAD, OFFICE OF THE
MANAGING DIRECTOR,
RESEARCH COORDINATOR,
MPI-CBG, MAX PLANCK
INSTITUTE OF MOLECULAR
CELL BIOLOGY AND GENETICS



Esther Lange
INDUSTRY LIAISON MANAGER,
ASCENION

ASSOCIATIONS, CLUSTERS



Nicolas Carboni
PRESIDENT,
RÉSEAU C.U.R.I.E.



Barbara Freischem
MANAGING DIRECTOR,
EBE - EUROPEAN
BIOPHARMACEUTICAL
ENTERPRISES



Yohan Grosjean
COMMUNICATION OFFICER,
AFSSI - THE FRENCH
ASSOCIATION OF
OUTSOURCING AND
INNOVATIVE COMPANIES



Jean-Louis Hunault
PRESIDENT, SIMV - THE
FRENCH ASSOCIATION OF THE
ANIMAL HEALTH INDUSTRY



Marco Pintore
GENERAL MANAGER,
BIOVALLEY FRANCE



Christian Policard
MEMBER OF THE BOARD,
CHAIRMAN OF THE BUSINESS
DEVELOPMENT
SUB-COMMITTEE,
FRANCE BIOTECH



Emilie Royere
GENERAL MANAGER,
EUROBIOMED



Etienne Vervaecke
GENERAL MANAGER,
EURASANTÉ & CLUBSTER-NHL

INVESTORS



Anta Gkelou
ANALYST,
SOFINNOVA PARTNERS



Frank Hensel
PRINCIPAL,
HIGH-TECH GRÜNDERFONDS



Jérôme Majoie
GENERAL MANAGER,
FOUNDATION
FOURNIER-MAJOIE



Daniel Parera
EXECUTIVE IN RESIDENCE,
TVM CAPITAL GMBH



Lotfi Yelles Chaouche
PARTNER,
THEODORUS FUND

TABLE OF CONTENTS

Organisers.....	4
Steering Committee.....	8
Sponsors.....	11

BIOFIT AGENDA.....	16
HOSTED EVENTS AGENDA.....	18

ONE-TO-ONE MEETINGS	
Partnering - Who will you meet?.....	20
Would-be CEO.....	22

PITCH SESSIONS	
Start-up Slams.....	25
Collaborative and Licensing Opportunity Presentations.....	28
Service Presentations.....	30
Animal Health Collaborative Opportunity Presentations.....	32

CONFERENCES	
PLENARY SESSION.....	35
TRACK 1 Best practices in academia-industry R&D collaborations.....	36
TRACK 2 Nurturing and licensing early-stage assets.....	40
TRACK 3 From pre-seed to Series A: Accessing early-stage investment.....	44
TRACK ANIMAL HEALTH HIGHLIGHTS.....	48

HOSTED EVENTS	
R&D Dating for Animal Health and Innovation.....	50
Translational Neuroscience.....	51
PIRX - Patient Innovation Xperience by Roche.....	52
European Project Imode.....	53

EXHIBITION	
Exhibitor List & Floor Plan.....	56
Exhibitor Descriptions.....	58

Sponsors.....	84
Partners.....	86



Strategic **PARTNERSHIP**
is at the heart of
fulfilling Pfizer's
purpose as we
work to translate
advanced science
and technologies
into medicines and
vaccines that
significantly improve
patients' lives.

www.pfizer.com/partners

Visit the Pfizer partnering website to learn more about:

- Our Areas of Interest
- Our Partnering Leadership
- Our Process
- Contact Information
- Partnering Highlights



SPONSORS

GOLD SPONSORS



PFIZER

www.pfizer.com

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. To learn more, please visit us on www.pfizer.com and follow us on Twitter at @Pfizer and @Pfizer_News, LinkedIn, YouTube and like us on Facebook at [Facebook.com/Pfizer](https://www.facebook.com/Pfizer).



SANOFI

www.sanofi.com

Sharing expertise can fast-track innovation:

We are a global life sciences company committed to pursuing pioneering, life-changing treatments that address unmet healthcare challenges. Innovative collaborations are one of the fulfilling ways we meet those goals and create value for all involved.

We are prioritizing our research efforts on delivering first- and best-in-class medicines - those with the potential to change people's life.

Accelerate the development of your ideas and assets:

Tap into our deep expertise in developing, registering and bringing products to market. Together, we have the ability to go further faster and touch more people with the most innovative initiatives.

Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

PURSuing INNOVATIVE THERAPEUTIC & DIAGNOSTIC SOLUTIONS IN METABOLIC & LIVER-RELATED DISEASES

TREATMENT

Pursuing
therapeutic
solutions

DIAGNOSTIC

Identifying
patients with
NASH & fibrosis

AWARENESS

Optimizing
standards of care

www.genfit.com

contact@genfit.com

@genfit_pharma

GENFIT

Copyright © 11 2019 GENFIT. All rights reserved. CORP-1915.

PUB MSD

SPONSORS

SILVER SPONSORS



GENFIT

www.genfit.com

GENFIT is a late-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutic and diagnostic solutions in metabolic and liver related diseases. Its most advanced drug candidate, elafibranor, is currently being evaluated in a pivotal Phase 3 clinical trial ("RESOLVE-IT") as a potential treatment for NASH, and GENFIT plans to initiate a Phase 3 clinical trial in PBC next year following its positive Phase 2 results. The company is also developing a new, non-invasive and easy-to-access blood-based in vitro diagnostic test to identify patients with NASH who may be appropriate candidates for drug therapy. Nasdaq and Euronext: GNFT.



MSD

www.msd.com

MSD has a strong history of success in translating cutting-edge research into life-saving medical breakthroughs. Our scientific advances have made a difference in the lives of millions of patients worldwide... and many of these advances were the result of partnerships. In 2016, more than 60% of our human health sales were attributable to alliance partnerships and patents and we continue to work with our partners in some of the most challenging areas of biomedical research. With more than 100 business development transactions since 2015, our team has experience working on collaborations from discovery to clinical-stage programs regardless of therapeutic area or modality. We believe that by working together we can play a major role in transforming global health care. Together we can invent for life.



MSD ANIMAL HEALTH

www.msd-animal-health.com

MSD Animal Health, is the global animal health business unit of MSD. Through its commitment to the Science of Healthier Animals®, MSD Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services. MSD Animal Health is dedicated to preserving and improving the health, well-being and performance of animals. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. MSD Animal Health is present in more than 50 countries, while its products are available in some 150 markets.

SPONSORS

BRONZE SPONSORS



ALMIRALL
www.almirall.us

Almirall is a leading global pharmaceutical company, focused in medical dermatology and headquartered in Barcelona. Our strong commitment is to improve patients' quality life while caring and listening to them. We work to offer innovative and differentiated medicines for skin conditions with high unmet need. We cover the whole of the drug value chain through an expert R&D organisation as well as key partnerships.



BAYER
www.bayer.fr

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2018, the Group employed around 117,000 people and had sales of 39.6 billion euros. Capital expenditures amounted to 2.6 billion euros, R&D expenses to 5.2 billion euros.



BOEHRINGER INGELHEIM
www.boehringer-ingelheim.com

Boehringer Ingelheim is a research-driven pharmaceutical company focused on improving the health and quality of life of patients. Working at the forefront of science and technology, our teams discover and develop innovative new medicines for the many diseases for which there are still no effective treatments. Independent and family-owned, we have the freedom to pursue our long-term vision so we can also begin the journeys of discovery that will help today's children face a healthier future.



EVOTEC
www.evotec.com

Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. Drug discovery solutions are provided in form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of innovative drug candidates and consulting arrangements.



IPSEN
www.ipsen.com

Ipsen is a global specialty-driven biopharmaceutical group focused on innovation and Specialty Care. The Group develops and commercializes innovative medicines in three key therapeutic areas – Oncology, Neuroscience and Rare Diseases. Its commitment to oncology is exemplified through its growing portfolio of key therapies for prostate cancer, neuroendocrine tumors, renal cell carcinoma and pancreatic cancer. Ipsen also has a well-established Consumer Healthcare business. With total sales over €2.2 billion in 2018, Ipsen sells more than 20 drugs in over 115 countries, with a direct commercial presence in more than 30 countries. Ipsen's R&D is focused on its innovative and differentiated technological platforms located in the heart of the leading biotechnological and life sciences hubs (Paris-Saclay, France; Oxford, UK; Cambridge, US).



NOVO NORDISK
www.novonordisk.com

Novo Nordisk is a global healthcare company with 95 years of innovation and leadership in diabetes care. We are committed to the discovery and development of innovative treatments for diabetes, obesity, haemophilia, NASH, atherosclerosis, heart failure, chronic kidney disease and we are seeking partnerships in all these indications. From molecule to market, our focus is on the patient. We are also committed to environmental and social responsibility.



ROCHE
www.roche.com

Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to invest heavily in research and development with CHF 11 billion in 2018. Alongside the broad internal pipeline, external innovation has always been a critical component of the Roche research and development strategy.

CONTRIBUTING SPONSORS



LFB
www.groupe-lfb.com

**Advent
France Biotechnology**

ADVENT FRANCE BIOTECHNOLOGY
www.adventfb.com



INNATE PHARMA
www.innate-pharma.com



ALZPROTECT
www.alzprotect.com



ONTOFORCE
www.ontoforce.com

DAY ONE

TUESDAY, DECEMBER 10TH

	Conferences and roundtable discussions			Pitch sessions	Partnering
7.30 am 9.00 am	☕ NAME BADGE PICKUP & WELCOME COFFEE				
9.00 am 9.30 am	SORMIOU ROOM PRESS CONFERENCE	LILLE ROOM Working with corporate venture funds	STRASBOURG ROOM What are the outcomes of long-lasting commitment between universities and pharmaceutical companies?	INNOV'AREA Collaborative and Licensing Opportunity Presentations	🤝 One-to-one meetings
9.30 am 10.30 am					
10.30 am 11.00 am	☕ NETWORKING BREAK				
11.00 am 12.30 pm	LILLE ROOM PLENARY SESSION What is pharma looking for nowadays?				
12.30 pm 2.00 pm	🍴 LUNCH			STRASBOURG ROOM 🍴 INVESTORS' LUNCH	
2.00 pm 3.00 pm	LILLE ROOM What are the milestones to be reached for an academic asset?	STRASBOURG ROOM Managing pre-competitive collaboration in Life Sciences	INNOV'AREA Start-up Slams: - Infection - Cell-therapy - Cardio-metabolic - Wound-care - Animal Health		🤝 One-to-one meetings
3.15 pm 4.15 pm	LILLE ROOM How can big data fuel collaborations between industry and academic institutions?	STRASBOURG ROOM Which funding models to accelerate anti-parasitic and anti-infectious innovation?			
4.15 pm 4.45 pm	☕ NETWORKING BREAK				
4.45 pm 6.15 pm	LILLE ROOM Challenging conventional wisdom: Is early-stage capital as satisfyingly available in Europe as we like to believe?	STRASBOURG ROOM How is AI based on wearables and sensors a major driver for the future of Animal Health and veterinary sciences?	INNOV'AREA Sponsor Presentations: - Sanofi - Pfizer - MSD - MSD Animal Health		
6.30 pm					



DAY TWO

WEDNESDAY, DECEMBER 11TH

	Conferences and roundtable discussions			Pitch Sessions	Partnering
7.30 am 9.00 am	☕ WELCOME COFFEE				
9.00 am 10.00 am	LILLE ROOM How to prepare your package for a due diligence by a pharma player?	STRASBOURG ROOM What are the recent successful industry-academia collaborations in Artificial Intelligence?	INNOV'AREA Animal Health Collaborative Opportunity Presentations		
10.00 am 10.30 am	☕ NETWORKING BREAK				
10.30 am 11.30 am	LILLE ROOM How to shape the corporate governance of biotech start-ups at their very first steps to make them successful?		INNOV'AREA Service Presentations		🤝 One-to-one meetings
11.45 am 12.45 pm	LILLE ROOM Which new forms of academia-industry partnerships to better mature assets?	STRASBOURG ROOM Would-be CEO Workshop			
12.45 pm 2.00 pm	🍴 LUNCH				
2.00 pm 3.30 pm	LILLE ROOM What's hot, what's not? What's on the investors' wishlist for 2020?	STRASBOURG ROOM Which promises to be delivered by high potential vaccines?	INNOV'AREA Start-up Slams: - Cancer - CNS		
3.30 pm 4.00 pm	☕ NETWORKING BREAK				
4.00 pm 5.30 pm	STRASBOURG ROOM What to ensure before the creation of a viable spinout opportunity?			INNOV'AREA Award Ceremony	



TRACK 1
Best practices in academia-industry R&D collaborations



TRACK 2:
Nurturing and licensing early-stage assets



TRACK 3:
From pre-seed to Series A: Accessing early-stage investment



ANIMAL HEALTH

HOSTED EVENTS AGENDA

DAY ONE – TUESDAY, DECEMBER 10TH



Translational
Neuroscience

EXHIBITION AREA

MORGIOU ROOM

MARSEILLEVEYRE ROOM

7:30 am
9:00 am

NAME BADGE PICKUP & WELCOME COFFEE

9:00 am
10:30 am

R&D dating for animal health and innovation

- 3D printing of personalised pharmaceutical solid dosage form: promises and challenges
- Fabrication of 3D printing filaments for pharmaceutical and biomedical applications
- Engineering of pharmaceutical cocrystals and salts: State of the art industrial approaches
- Carbamazepin cocrystals revisited
- Nanofabrication techniques for enhanced drug delivery: from complex nanofibers to nanogels

Translational Research Infrastructures

10:35 am

10:30 am
11:00 am

NETWORKING BREAK

11:00 am
12:30 pm

R&D dating for animal health and innovation

- Hot melt extruded polysaccharide blends for controlled drug delivery
- Electrospun oral formulations for colon targeting
- Investigation of complex molecular dynamics in multi-component systems
- Stability and mobility of multicomponent pharmaceutical materials
- Starch matrix tablets for controlled drug delivery

Role of public and industry actors in neuroscience translational research – What mechanisms and resources to support translation up to phase 2?

12:35 pm

12:30 pm
2:00 pm

LUNCH

2:00 pm
3:30 pm

R&D dating for animal health and innovation

Stakes of training in translational neuroscience research – State-of-the-art and needs of academia and industry

4:00 pm
5:40 pm

STRASBOURG ROOM

How is AI based on wearables and sensors a major driver for the future of Animal Health and veterinary sciences?



One-to-one meetings

Advanced translational projects

5:30 pm
6:30 pm

6.15 pm

R&D dating for animal health and innovation

6:30 pm



HOSTED EVENTS AGENDA

DAY TWO – WEDNESDAY, DECEMBER 11TH



EXHIBITION AREA

MARSEILLEVEYRE ROOM

7:30 am
9:00 am

NAME BADGE PICKUP & WELCOME COFFEE

9:00 am
9:15 am

INNOV'AREA

Introduction

9:30 am
10:00 am

Animal Health Collaborative
Opportunity Presentations

Access and Financing Innovation

10:00 am
10:30 am

R&D dating for animal health and innovation

10:30 am
11:00 am

NETWORKING BREAK

11:00 am
12:30 pm

R&D dating for animal health and innovation

e-Health

12:30 pm
2:00 pm

LUNCH

2:00 pm
3:30 pm

STRASBOURG ROOM

Which promises to be delivered by high potential vaccines?

Data

3:30 pm
4:00 pm

NETWORKING BREAK

4:00 pm
5:15 pm

R&D dating for animal health and innovation

Social Innovation


5:15 pm
6:00 pm

Conclusion

6:00 pm
6:30 pm

PARTNERING

**48 hours to meet
your future project partners,
obtain funding and
accelerate innovation**



WHO WILL YOU MEET?



Partnering at BioFIT is powered by **inova**

Malin Lilleøre is an employee in Novo Nordisk and works in CMC Development in Denmark




“At Novo Nordisk, we believe that partnerships, based on long-term commitment and mutual interest, are key to fostering innovation. We work closely with universities and biotech companies worldwide to bring about innovation.”
Mads Krogsgaard Thomsen, Chief Science Officer of Novo Nordisk

Changing patients' lives **together**



**Download the «Inova Event» app
to receive your agenda updates**

Organise your agenda | Request and manage meetings | Mobile messaging



WOULD-BE CEO

Are you a bioentrepreneur seeking a project? Or do you have projects needing a CEO?

As talented CEOs are frequently sought-after by many actors of the biotech industry, this Would-be CEO session will bring together representatives of emerging start-ups, technology transfer offices, incubators and investing networks as well as CEOs and would-be CEOs to address this important issue.

Any bioentrepreneur looking for a project to get involved in is welcome to join the Would-be CEO session. Any incubator, tech transfer entity or scientific founder looking for an entrepreneur to lead their start-up projects is also welcome to join.

December 11th | 11.45 am - 12.45 pm | STRASBOURG ROOM

Bioentrepreneurs workshop:

- Panorama of European entrepreneurial training programmes
- How do I find the right co-founders? Which networks to activate? How do we find the risk takers and the co-entrepreneurs? Hear from savvy entrepreneurs and investors to receive feedback and best practices.



MODERATOR:

Caroline Ramspacher
Innovation & Entrepreneurship Partner
Eurasanté



Luigi Costa
Entrepreneur In Residence
Sofinnova Partners



Matthieu Coutet
Managing Partner
Advent France Biotechnology

Networking cocktail:

This networking moment is the occasion to establish collaborations between future entrepreneurs and projects in need of CEOs.

PUB MSD ANIMAL



PITCH SESSIONS

The early-stage innovations you need

The BioFIT pitch sessions offer the opportunity to detect the most innovative and promising start-ups, R&D projects, licensing opportunities and services in order to foster partnerships and business development in the Life Sciences field.

The winners will be awarded as the most innovative start-up, the most promising technology, the most innovative offer and the most innovative animal health project in Life Sciences during the Award Ceremony:

December 11th
From 4.00 pm
Innov'Area (Exhibition Hall)



START-UP SLAMS | AGENDA

The Start-up Slams are a great opportunity for **young companies** (and particularly start-ups seeking to raise a seed or a Series A financing round) to showcase their project in front of potential partners and investors.

Sponsored by:



December 10th | 2.00 pm - 4.15 pm | Innov'Area

INFECTION

MediSieve Ltd. 🇬🇧

Sepsis | Blood-borne diseases | Platform therapeutic

LactaPure 🇩🇰

Microbiome | Antibiotic resistance | Diabetes

CELL-THERAPY

BioFOR-Nerve 🇮🇹

Biocompatible Organ Regeneration | Peripheral Nerve Regeneration | Nerve Hollow Tube/Connector

INNOVGEL 🇫🇷

Hydrogels for 3D cell culture | Bio-inks for bioprinting | Tissue engineering and regenerative medicine

TRINCE 🇧🇪

Transfection | Photoporation | Cell-based therapy

DenovoMATRIX GmbH 🇩🇪

Coating | Stem cells | Chemically Defined

START-UP SLAMS | AGENDA

December 10th | 2.00 pm - 4.15 pm | Innov'Area

CARDIO-METABOLIC

ENTEROSYS

Type 2 diabetes | Enteric nervous system | Gut-brain communication

SKILLCELL

Diabetes | Urine test | Diagnostic

Balmes Transplantation

Ischemia-reperfusion injury | Acute Kidney Injury | Chronic Kidney Disease

WOUND-CARE

EvoBiotech

Biotech | Pharma | Medical device

REGULAXIS

Gonarthrosis | Cartilage | Peptide

ANIMAL HEALTH

AND Biopharma

Inhibitory action | DNA Self toxicity | Extracellular DNA (exDNA)

PathoSense

Rapid diagnostic | Infectious diseases | Animal health

Biocheck.ugent

Biosecurity | Farm | Coaching

START-UP SLAMS | AGENDA

December 11th | 2.00 pm - 3.30 pm | Innov'Area

CANCER

Apmonia Therapeutics

Immuno-oncology | Drug peptides | Precision medicine

SiBreaX AG

Drug development | Lung cancer | Drug Delivery

Immune insight

Immuno-monitoring | Regulatory T cells (Tregs) | Predict and anticipate clinical trials or therapeutic treatments failure

Nanoligent.SL

Metastasis | Oncology | Selective

SideROS

Small molecules | Refractory/resistant cancer | Persister cancer cell

ADCendo

Cancer | Antibody drug conjugate (ADC) | Established In vivo proof of concept

Elphogene

Liquid biopsy | CtDNA | Colorectal cancer

CNS

Agent

Alzheimer's | Machine Learning | Blood diagnosis

MT-act

Tauopathy | Neurodegeneration | Optic nerve

COLLABORATIVE AND LICENSING OPPORTUNITY PRESENTATIONS | AGENDA

The Collaborative and Licensing Opportunity Presentations are a great opportunity for TTOs, universities, research institutes and companies to showcase their early-stage technologies in front of potential partners, in order to entail a collaborative project and/or a licensing deal.

December 10th | 9.00 am - 10.30 am | Innov'Area

DIAGNOSTIC

PEPperPRINT GmbH

Peptide | Neoepitopes | Biomarker

University of Pardubice

Lipidomics | Mass spectrometry | Cancer screening

Eötvös Loránd University, Faculty of Sciences, Budapest

Machine learning | Parkinsons' disease | Diagnosis

CNS

Smoke Free Therapeutics

Smoking cessation | Immunotherapy | Natural extract

Alcediag

Biomarkers | Epigenetics | Psychiatry

COLLABORATIVE AND LICENSING OPPORTUNITY PRESENTATIONS | AGENDA

CELL-THERAPY

Central European Institute of Technology (CEITEC), Brno University of Technology

Hybrid implant | Interbody fusion | Lumbar spine

Institute of Experimental Medicine CAS & Bioinova

Cell therapy | Mesenchymal stem cells | Clinical grade solution

INFECTION

SATT Linksium

Antibiotic | Bacterial resistance | Gram +

Ai-biopharma

Hepatitis B virus | Liver targeting technology | Viral Capsid Assembly and Polymerase Inhibitors

SERVICE PRESENTATIONS AGENDA

The Service Presentations are a great opportunity for **service providers and technology platforms** with an **innovative offer** to showcase their offers in front of potential clients.

December 11th | 10.30 am - 12.45 pm | Innov'Area

RESEARCH TOOLS

DNAlytics

Multi-marker data analysis | Predictive modelling | From research to clinical routine

Velabs therapeutics GmbH

Droplet based microfluidics | HTS screening | Functional antibodies on complex targets (like GPCRs)

e-Zyvec

Genetic engineering | Plasmid creation | Co-design

Ximbio

New and unique reagents | Simplified Reagent Commercialisation and MTA licensing | A fully funded internship programme

DRUG DELIVERY TOOLS

DIANA Biotechnologies

Ultrasensitive biomarker detection | High-throughput screening | Selectivity profiling

NEUWAY Pharma GmbH

CNS Drug Delivery Platform | Treatment of CNS-related diseases | Partnering project with pharma companies

SERVICE PRESENTATIONS AGENDA

PRECLINICAL TOOLS

CYNBIOSE

Non Human Primate | Immunotherapies | Delayed-Type Hypersensitivity

Repositive

Pre-clinical drug development | Precision medicine | Cancer therapy

COMET Biobank

Tissue biobank | Metabolic diseases | Quality management system

CLINICAL TOOLS

Longenesis Limited

Clinical data | Consent | Life data economics

PRODUCTION TOOLS

DELPHARM

Hot Melt Extrusion (HME) | Early formulation | Poorly soluble drug

Enantia SL

Cocrystals | Purification | Scalable

Holodiag

X-ray powder diffraction | Reference samples | Polymorphic forms

ANIMAL HEALTH COLLABORATIVE OPPORTUNITY PRESENTATIONS | AGENDA

December 11th | 9.00 am - 10.00 am | Innov'Area

EnvA - Veterinary National School of Alfort: EquiSym 🇫🇷

Horse | Locomotion | Lamenesses | Biomechanics

EnvA - Veterinary National School of Alfort 🇫🇷

Therapeutic development | Broad-spectrum activity | Host-targeting agent

ZOPOLE development: CLOSTRICOX 🇫🇷

Clostridium perfringens | Clostridium botulinum | Experimental models, chickens, feed

INGULADOS 🇪🇸

Bacteriocins | Synergistic antimicrobials | One Health

University of Tours 🇫🇷

Congenital neosporosis | Mucosa-nanoparticle | Vaccine

SATT AxLR 🇫🇷

Natural compound | Antibacterial | Aquaculture



CONFERENCE PROGRAMME

Steered by a prestigious Committee, the BioFIT conference programme brings together bright minds to debate on innovation-focused topics, to foster learning, inspiration and wonder – and provoke conversations that matter.

Over 80 international experts will discuss current stakes of the sector related to innovative academia-industry collaborations, early-stage assets, investment as well as animal health:

1 TRACK

**Best practices in academia-industry
R&D collaborations**

2 TRACK

**Nurturing and licensing
early-stage assets**

3 TRACK

**From pre-seed to Series A:
Accessing early-stage investment**

TRACK

Animal Health highlights

PLENARY SESSION

WHAT IS PHARMA LOOKING FOR NOWADAYS?

December 10th | 11.00 am - 12.30 pm | Lille Room

A lot of pharma companies declare that they no longer want to be purely developers of drugs, and thus they progressively transition to become healthcare solution providers, trying to seek broader solutions to answer the patient needs, and changing the way they look at assets: What does it mean for the industry in terms of orientation of their scouting efforts, particularly for early-stage assets?

This session aims to understand pharma's viewpoint, the consequences for the orientation of deals, the way it is going to influence the relationships with academia and biotech start-ups. How does this strategic intention modify the type and the nature of deals that pharma have with start-ups & academic institutions? How is it affecting early-stage licensing deals?



MODERATOR:

X
xxx
xxx




Sascha Bucher
Head of Global Transactions and
Head Roivant Basel Pharma
Roivant Sciences Inc. 



Khatareh Ahmadi
Executive Director,
Oncology Sourcing
Merck Sharp & Dohme 



James Eshelby
Executive Director, Head of IMI and
Global Public Private Partnerships -
Emerging Science & Innovation
Pfizer 



Tomas Landh
Innovation Sourcing VP,
Senior Principal Scientist Search
and Evaluation
Novo Nordisk 

CONFERENCE PROGRAMME

1 TRACK

Best practices in
academia-industry
R&D collaborations

December 10th | 9.00 am - 10.30 am | STRASBOURG ROOM

WHAT ARE THE OUTCOMES OF LONG-LASTING COMMITMENT BETWEEN UNIVERSITIES AND PHARMACEUTICAL COMPANIES?

To which needs do these numerous collaboration schemes answer? What are the specificities of these agreements in terms of management models and R&D means mutualisation. Are short-term reports and industry constraints coherent with multi-years academic agreements?



MODERATOR:

Gerald Law
Chief Executive
Innovation DB
(UK Innovation Forum) 🇬🇧



Jochen Maas
General Manager,
Research & Development
Sanofi 🇩🇪



Christopher Keely
Senior Business
Development Manager
Trinity College Dublin 🇮🇪



Ulrik Lytt Rahbek
Vice President
Novo Nordisk 🇩🇰

December 10th | 2.00 pm - 3.00 pm | STRASBOURG ROOM

MANAGING PRE-COMPETITIVE COLLABORATION IN LIFE SCIENCES: TESTIMONIALS ON OUTCOMES & LIMITS OF EUROPEAN CONSORTIA

Which research topics are considered good candidates for competitive consortia at the time of precision medicine? Are the current collaborative models (IMI, H2020...) adapted to the research needs? How to balance each party's interests and define the domain of precompetitive research. How can IP problematics be managed?



MODERATOR:

Kostas Skarvelakis
Innovation Business
Development Director
Ayming 🇫🇷



Lee Wen Hwa
CEO
Action Against AMD 🇬🇧
Director – Affordable medicines Programme,
Oxford Martin School
University of Oxford 🇬🇧



Nicolas Creff
Senior Manager
Research partnerships
EFPIA 🇧🇪



Karen Godbold
Senior Director, Global Public-
Private Partnerships
Pfizer 🇬🇧

December 10th | 3.15 pm - 4.15 pm | LILLE ROOM

HOW CAN BIG DATA FUEL COLLABORATIONS BETWEEN INDUSTRY AND ACADEMIC INSTITUTIONS?

How can consolidating and mutualising data between industrial and academic players unlock the full potential of these partnerships? How can we make these data available to pharma and how can we make use of big data to fuel the pharma pipeline? Which collaboration models have emerged around big data? How is the central status of big data already entailing academia-industry collaborations?



MODERATOR:

Cormac Sheridan
Journalist
BioWorld



Magali Touroude-Pereira
CEO
YesMyPatent



Hans Constandt
CEO
Ontoforce



Francesco Ruespo
CBO
AcademicLabs



Frédéric Caillaux
Deputy General
manager Innovation
INPI

December 11th | 9.00 am - 10.00 am | STRASBOURG ROOM

WHAT ARE THE RECENT SUCCESSFUL INDUSTRY-ACADEMIA COLLABORATIONS IN ARTIFICIAL INTELLIGENCE?

What are the good examples of partnerships in this field? How have they proved to be fertile in innovation for the benefit of both parties?



MODERATOR:

X
xxx
xxx



Nora Khaldi
CSO
Nuritas



Meriem Sefta
Head of Partnerships
Owkin



Rakesh Uppal
Cardiac Surgeon
Barts and the London
School of Medicine

almirallshare

an open innovation platform
created to foster partnerships
in dermatological research.

Sharing innovation, our purpose

Explore our collaboration opportunities at
sharedinnovation.almirall.com



almirall.com



FOR MANY AN ACTIVE LIFE | OUR SCIENTISTS STOPS FAR TOO EARLY | WON'T ACCEPT THAT



By 2050 the world's population over 60 will have doubled to two billion, making age-related illness an even greater challenge for society. That's why we're seeking to help people stay healthier and more active in later life, be it through more targeted treatments

for cancer and cardiovascular conditions, solutions for eye diseases, or ways to keep those with arthritis moving. Because life shouldn't stop at 60— not by any means. To find out how our innovations are helping to change lives for the better, visit our website : www.bayer.fr.

Science for a **better life**

CONFERENCE PROGRAMME

2 TRACK

Nurturing and licensing early-stage assets

December 10th | 2.00 pm - 3.00 pm | LILLE ROOM

WHAT ARE THE MILESTONES TO BE REACHED FOR AN ACADEMIC ASSET?

How to value an early-stage though promising asset? To what extent do experimented actors help the bio-entrepreneur to aim for a realistic maturation and validation roadmap? How do they help the managing team to understand value inflection points? How do the industry players (pharma, biotech, VC) handle this issue of granting of value to those assets? How could industrial players help academic institutions and TTOs avoid making mistakes at the very early development stages?



MODERATOR:
Gary Breit
CEO
Breit Ideas 🇺🇸



Benjamin Soffer
Head of Strategic Corporate
Partnerships
King's College 🇬🇧



Matthieu Coutet
Managing Partner
Advent France
Biotechnology 🇫🇷



X
xxx
X

December 11th | 9.00 am - 10.00 am | LILLE ROOM

HOW TO PREPARE TO DUE DILIGENCE FROM A PHARMA PLAYER?

What are the key questions an academic project should address to ensure a valuable licensing deal in the view of pharmaceutical industries? How can a biotech company prepare for a due diligence by big pharma? Which areas are usually underestimated when preparing for a due diligence? What is an efficient due diligence plan? How to prepare an attractive asset to pharma and investors? What are the fundamentals of due diligence? What are the legal aspects to get prepared to?



MODERATOR:
X
xxx
xxx



Louise Jonshammar
Attorney at law
AWA 🇸🇪



Klaus Dembowsky
CEO
amcure 🇩🇪



X
xxx
xxx

WHICH NEW FORMS OF ACADEMIA-INDUSTRY PARTNERSHIPS TO BETTER MATURE ASSETS?

Numerous tools have been created in the last years, how do these early-stage financing vehicles work? On which bases do they ground funds allocation? What are the expectations of the limited partners? Who are the players involved in such investment tools, and what do they await from their involvement in such early-stage funding and investment tools?



MODERATOR:
Avishai Levy
Managing Partner
Agbiopro



Youness Karout
Researcher
University of Lille



Mark Slack
VP Academic Partnerships
Evotec



X
xxx
xxx

WHAT TO ENSURE BEFORE THE CREATION OF A VIABLE SPINOUT OPPORTUNITY?

What does viable mean for TTOs, and do we have the same definition everywhere? On which grounds are TTOs advising to create a spin-off rather than out-licensing the IP or a contract-based R&D collaboration? Which are the benefits, limits, constraints and indication of the spin-out model? What are the key factors to create a well-conceived spin-off company, how to exploit and maximise the value creation?



MODERATOR:
Rafaela Kunz
Open Innovation Expert
INSEA Consulting



Jürgen Walkenhorst
Head of Technology Transfer
University of Vienna



Anna Białek Jaworska
Professor
University of Warsaw



X
xxx
xxx

Working together for better health

We set the bar high for innovation. Motivated by patients, driven by science and inspired by our growing global community of partners, we are working hard to discover and develop the next generation of pioneering medicines. If you share our goal of researching and developing new medications to improve the health of people around the world, please join us...

Working together for better health

Innovation @ Boehringer Ingelheim

For more information visit:
www.boehringer-ingelheim.com/partnering



PUB EVOTEC

CONFERENCE PROGRAMME

3 TRACK

From pre-seed to Series A: Accessing early-stage investment

December 10th | 9.00 am - 10.30 am | LILLE ROOM

WORKING WITH CORPORATE VENTURE FUNDS?

What are the benefits or constraints to go to a corporate venture tool? Is it better to go with a pharma player that wants to be a limited partner in existing funds rather than corporate ventures? As both have fundamentally different missions, what are the validating and limitation effects of working with a corporate VC? How to balance these two effects?



MODERATOR:

Etienne Adriansen
Deputy Director
Healthcare Denmark 🇩🇰



Cheryl Zimmerlin
Principal
M Ventures 🇧🇪



Lionel Carnot
Partner
Earlybird Venture Capital 🇫🇷



Joachim Vogt
Director, Search and
Evaluation, Western Europe
AbbVie 🇩🇪



Xxxx
xxx
xxx

December 10th | 3.15 pm - 4.15 pm | STRASBOURG ROOM

WHICH FUNDING MODELS TO ACCELERATE ANTI-PARASITIC AND ANTI-INFECTIOUS INNOVATION?

Which funding to support new vaccines, drugs and treatment strategies in Africa? What is the role of philanthropic funding? How can foundations and governments form alliances to fund better R&D?



MODERATOR:

Isaac Haq
Analyst
ArchiMed Group 🇫🇷



Santiago Ini
Director of Business Development
Technion Technology Transfer 🇮🇱



Yann Ferrisse
Head of Business Development
and Analysis
GARDP 🇫🇷



Julie Brady
Business Development Manager
University of Dundee 🇬🇧

December 10th | 4.45 pm - 6.15 pm | LILLE ROOM

CHALLENGING CONVENTIONAL WISDOM: IS EARLY-STAGE CAPITAL AS SATISFYINGLY AVAILABLE IN EUROPE AS WE LIKE TO BELIEVE?

How is it crucial to question the accepted common idea that Europe only lacks bigger funds for bigger roundtables and for more mature companies? Compared to European later-stage investment markets which are positively underfunded, it seems at first glance that the early-stage capital market is healthy and well-fuelled, but is it genuinely the case? Is the European early-stage capital market as rich in players and capital as it is said to be?



MODERATOR:

Cyril Teixeira Da Silva
Investment Officer
European Investment Bank 🇵🇹



Kevin Johnson
Partner
Medicxi 🇬🇧



Rémi Droller
Managing Partner
Kurma Partners 🇫🇷



Tim Haines
Managing Partner
Abingworth 🇬🇧

December 11th | 2.00 pm - 3.30 pm | LILLE ROOM

WHAT'S HOT, WHAT'S NOT? WHAT'S ON THE INVESTORS' WISHLIST FOR 2020?

How do the deals and lessons-learned from 2019 investment let us peak at what can be expected for 2020? What are the tips for success for next year? Which therapeutic area will gain or reinforce interest from the VCs? How can you make sure that your business will be on VC's radar?



MODERATOR:

Kevin Grogan
Managing editor
Scrip, Informa 🇬🇧



Sylvain Sachot
Investment Director
Asabys Partners 🇪🇸



Ingrid Teigland Akay
Managing Partner
Hadean Ventures 🇳🇴



João Ribas
Associate
Novo Seeds 🇵🇹

December 11th | 10.30 am - 11.30 am | LILLE ROOM

HOW TO SHAPE THE CORPORATE GOVERNANCE OF BIOTECH START-UPS AT THEIR VERY FIRST STEPS TO MAKE THEM SUCCESSFUL?

Beyond that the sole CEO appointment, how to cope with a pre-established governance from an academic spin-off? How can clashes of culture between researchers and industrials be beneficial and craft a balanced managing team? How are VCs expressing their demands and expectations and how are they filled up? To what extent is leaning on international strategic and scientific committees as soon as they are born a recipe of success?



MODERATOR:

X
xxx
xxx



Luigi Costa
Entrepreneur In Residence
Sofinnova Partners 🇫🇷



X
xxx
xxx



X
xxx
xxx

WE LISTEN TO AND LEARN FROM PATIENTS EVERY DAY...

Caroline
Laboratory Technician, R&D
Signes, France

We are dedicated to improving patients' lives through innovative medicines in Oncology, Neuroscience and Rare Diseases. Because patients can't wait.

www.ipsen.com

IPSEN
Innovation for patient care

CONFERENCE PROGRAMME



Animal Health highlights

December 10th | 4.30 pm - 6.00 pm | STRASBOURG ROOM

HOW IS AI BASED ON WEARABLES AND SENSORS A MAJOR DRIVER FOR THE FUTURE OF ANIMAL HEALTH AND VETERINARY SCIENCES?

What is the understanding of AI technologies and machine learning within the animal health industry? With the huge amount of data provided by wearables and sensors, how can data be utterly exploited? How is the future lying in real-time predictive analysis? How is AI bringing changes in business models through automated veterinary diagnostic tools?

MODERATOR:



Klaus Hellmann
CEO
Klifovet AG



Pauline Ezanno
Researcher
French National Institute for
Agronomic Research



Timothée Audouin
Animal e-Health consultant



Scott Brown
HEAD of Research &
Development
Zoetis

December 11th | 2.00 pm - 3.30 pm | STRASBOURG ROOM

WHICH PROMISES TO BE DELIVERED BY HIGH POTENTIAL VACCINES?

How can international and multidisciplinary approaches like the SAPHIR European project help develop innovative vaccination strategies? How are these kinds of projects integrating vaccination in a global health management system? What are the outcomes and expected developments in terms of vaccines production of these multi-million international project? How are these vaccines strengthening the profitability of food systems?



Jean-Pascal Marc
Corporate Product
Innovation Director
Virbac



Sabine Riffault
Director of research
French National Institute for
Agricultural Research



Jean-Christophe Audonnet
Senior Director,
International R&D Governance,
Coordinator of ZAPI IMI Project
Boehringer Ingelheim



Belen Barreiro
General Director
INGENASA

HOSTED EVENT

R&D DATING FOR ANIMAL HEALTH AND INNOVATION

December 10th & 11th | 9.00 am - 6.30 pm | EXHIBITION AREA



BioFIT 2019 hosts the 5th edition of the "R&D dating for Animal Health and Innovation" business convention, at the French association for the animal healthcare industry (SIMV)'s initiative, on December 10th and 11th, 2019 in Marseille.

Today, public-private and private-private partnerships are thought to be the leverage that is needed for innovation. That is why the SIMV launched the "R&D dating for Animal Health and Innovation", which strives to initiate high-level exchanges between research departments of the veterinary medicine and diagnostics industry and public research, as well as with biotechnology companies (start-ups).

By enabling face-to-face encounters, the event enhances the visibility of cutting-edge research in France and in Europe, encourage investments and lead to therapeutic innovation.

Animal health-related roundtable discussions during BioFIT:

- How is AI based on wearables and sensors a major driver for the future of Animal Health and veterinary sciences?
- Which promises to be delivered by high potential vaccines?

Organised by:



 simv.org

Contact: secretariat@simv.org

HOSTED EVENT

TRANSLATIONAL NEUROSCIENCE

December 10th | 9.00 am - 5.40 pm | MARSEILLEVEYRE ROOM



Translational Neuroscience research helps to provide R&D continuum from discovery to clinical phases by gathering multidisciplinary expertise, state-of-the-art technology platforms and innovative methodologies.

This event highlights innovative translational research for neurodegenerative diseases with a market focus. Thus, academia-industry relationships will be developed not only from the science and technology point of view but also through training / education required to constantly remain at the forefront of innovation. This new edition gathers experts in neurodegenerative diseases and foster interactions between researchers, clinicians, biotech and pharmaceutical companies.

THE PROGRAMME IN A NUTSHELL

9.00 - 10.30 am Session I Translational Research Infrastructures

DHUNE – Olivier Blin (DHUNE director)
NEURATRIS – Philippe Hantraye (MIRcen (CEA) and NeurATRIS)
Brain diseases: Advances, challenges and obstacles – Catherine Lubetzki (Pitié-Salpêtrière Hospital)

11.00 am - 12.30 pm Round table I

Role of public and industry actors in neuroscience translational research – What mechanisms and resources to support translation up to phase 2?
Moderator: Toni Andreu – CSO EATRIS-ERIC
Panel: Angel Cedazo-Miguez (Sanofi), Aline Jourdain (BPI), Michel Khrestchatsky (Vect-Horus), Emmanuel Le Boudier (Eurobiomed), Catherine Lubetzki (Pitié-Salpêtrière Hospital), Bruno Marroni (Protisvalor)

2.00 - 3.30 pm Round table II

Stakes of training in translational neuroscience research – State-of-the-art and needs of academia and industry
Introduction of a market study on Translational neuroscience training by Vincent Gleize (Erdyn)
Moderator: François Féron – NeuroSchool Director
Panel: Olivier Blin (DHUNE), Marc Dhenain (NeurATRIS and MIRcen), Corinne Grenier (KEDGE Business School), Rosan Vegter (EATRIS-ERIC)

4.00 - 5.30 pm

Advanced translational projects

Lionel Lamothe (Exostim), Mathieu Charveriat (Theranexus), Michel Khrestchatsky (Vect-Horus), Sylvie Claeysen (Montpellier University), Philippe Verwaerde (AlzProtect)

Translational Neuroscience partners:

Contact: ali.ait-ikhlef@neuratris.com



Institutional support of Roche

HOSTED EVENT

PIXR – PATIENT INNOVATION XPERIENCE BY ROCHE

December 11th | 9.00 am - 6.30 pm | MARSEILLEVEYRE ROOM



Roche is organising **PIXR – Patient Innovation Xperience** during BioFIT 2019. The day is dedicated to conferences, round-tables and pitches around Health Innovation. 4 themes are discussed:

- Access and Financing Innovation
- Data
- E-Health
- Social Innovation

PROGRAMME:

9.00 - 9.15 am	Introduction by: Mr Renaud Muselier , President of the Sud Provence-Alpes-Côte d'Azur Region
9.30 - 10.30 am	Access and Financing Innovation
10.30 - 11.00 am	Networking break
11.00 am - 12.30 pm	E-Health
12.30 - 2.00 pm	Lunch
2.00 - 3.30 pm	Data
3.30 - 4.00 pm	Networking break
4.00 - 5.15 pm	Social Innovation
5.15 - 6.00 pm	Conclusion by: Mr André Comte-Sponville , Writer, Professor, Philosopher, author of the famous "Petit traité de grandes vertus" Mr Jean-François Brochard , President, Roche France

HOSTED EVENT

EUROPEAN PROJECT IMODE

December 11th | 9.00 am - 12.35 pm | MORGIOU ROOM



IMODE is organising its fourth annual convention during BioFIT with a morning of conferences and one-to-one meetings during the afternoon.

PROGRAMME:

9.00 - 9.25 am	Dr Sheng Qi , University of East Anglia "3D printing of personalised pharmaceutical solid dosage form: promises and challenges"
9.25 - 9.35 am	Roxanne Khalaj , PhD, University of Greenwich "Fabrication of 3D printing filaments for pharmaceutical and biomedical applications"
9.35 - 10.00 am	Dr Steven Ross , University of Greenwich "Engineering of pharmaceutical cocrystals and salts: State of the art industrial approaches"
10.00 - 10.10 am	Luisa Roca Paixao, PhD , University of Lille "Carbamazepin cocrystals revisited"
10.10 - 10.35 am	Dr Duncan Craig , University College London "Nanofabrication techniques for enhanced drug delivery: from complex nanofibers to nanogels"
10.35 - 11.00 am	Break
11.00 - 11.25 am	Dr. Youness Karrouit , University of Lille "Hot melt extruded polysaccharide blends for controlled drug delivery"
11.25 - 11.35 am	Zuzana Hlaskova , PhD, University of East Anglia "Electrospun oral formulations for colon targeting"
11.35 - 12.00 pm	Natalia T. Correia , University of Lille "Investigation of complex molecular dynamics in multi-component systems"
12.00 - 12.10 pm	Jeanne-Annick Bama, PhD , University of Lille "Stability and mobility of multicomponent pharmaceutical materials"
12.10 - 12.35 pm	Nicolas Descamps , Roquette "Starch matrix tablets for controlled drug delivery"

IMODE is a collaborative research project for multicomponent pharmaceutical products (co-amorphous and co-crystals) and medical devices that are loaded with bioactive molecules. Started in 2016, the IMODE project is funded by the European Interreg 2 Seas programme and co-financed by the European Regional Development Fund (ERDF).

The project's overall objective is to bring together the specific transdisciplinary skills and experiences of partners (academic research groups, development agencies, SMEs) in order to provide the 2 Seas Area with strategic advantages for innovative pharmaceutical and medical applications. The IMODE project is motivated by an unmet need to develop solutions to addressing societal challenges to improve healthcare and provide novel and effective medication for various cardiovascular or gastro-intestinal conditions that lack or have inadequate treatment, all while keeping medical costs low.

IMODE partners:

Contact: slebrun@clubster-nsl.com

project-imode.eu



BIO *party*

DECEMBER
10TH
FROM
6.30 PM

ORANGE
VELODROME
STADIUM

SALON DES LÉGENDES

NETWORKING | MUSIC | DANCING | COCKTAILS
PHOTOBOOTH | TABLE FOOTBALL & BOULES



Biofit

FOSTERING
INNOVATION
& TRANSFER



PARTNERING

TO ADVANCE GLOBAL HEALTH



www.sanofi.com

Global.Partnering@sanofi.com

54 Rue La Boétie
75008 Paris



EXHIBITION LIST & FLOOR PLAN

EXHIBITORS

3M

STAND D20

www.3m.com/3M/en_US/bioprocessing-us

3M Separation and Purification Sciences Division provides cutting edge separation and purification technology and products for biopharmaceutical companies involved in production of recombinant proteins, plasma fractionation products, vaccines and small molecule drugs. Using 3M's innovative material science platforms, we help companies optimize their processes, improve product safety and increase manufacturing efficiencies, thereby, improving lives everywhere as a trusted supplier of purification.

AFSSI

STAND D21

www.afssi.fr

The AFSSI, the French Association of Service and Innovation Companies for the Life Sciences has the desire to unite French companies of services and technological innovation in the strategic field of Life Sciences. These innovative companies evolve in the pre-clinical phases, but also clinical, constitute the force of our sector; dynamic and highly qualified actors, constituting a diversified fabric of scientific providers essential to the development of industries in the Life Science

AMYLGEN

STAND E23-4

www.amylgen.fr

AMYLGEN is a privately owned contract research organization (CRO) offering a unique combination of validated in vivo models and a full range of biochemical and morphological testing allowing fast and predictive screening of the effects of drugs and nutraceuticals on brain health.

ATLANPOLE BIOTHÉRAPIES STAND E13

www.atlanpolebiotherapies.com

Atlanpole Biotherapies is a competitiveness cluster involved in the medicine of tomorrow. It is focused for the development of new therapies, immunotherapy, regenerative medicine and radiopharmaceuticals, on the bio-medicine value chain from target discovery to clinical evaluation, completed by digital and nutrition approach. The projects of our network of 230 members, both academic and industrial, show the excellence of our expertise in personalized medicine.

ADMESCOPE LTD.

STAND I25

www.admescope.com

Admescope provides the pharmaceutical, biotechnology and veterinary industry tailor made ADME-Tox services. Our service offering covers research services for peptides, biologics and small molecules and is widely spread over the whole ADME-Tox area. The right assays are available, whether in the discovery or lead optimisation phase. The level of data interpretation can be customized according to customer preferences. Currently Admescope serves customers in 27 countries on four continents.

AGRO-BIO ANTIBODIES STAND21 /4

www.agro-bio.com

Agro-Bio provides Antibody services for life sciences industries. Customized anti-idiotypic and anti-drug antibodies. Specific anti-HCP antibodies and HCP ELISA kits (coverage 2D). Biacore platform, affinity and kinetics, CQA: active concentration, Fc receptor binding... Identify antibody-binding sites on an antigen (Epitope Mapping). For your diagnostics kits with our customized polyclonal/ monoclonal antibody development and our large-scale antibody production.

**ANTAPODIA THERAPEUTICS;
KUPFFER BIOTHERAPEUTICS**

www.antapodia.com

STAND F21

www.kupfferbio.com

Antapodia Therapeutics and Kupffer Biotherapeutics are subsidiaries of Stempodia Corporation, a science-driven biopharmaceutical startup providing breakthrough solutions for advanced and metastatic cancers. The company's first-in-class invadopodia-targeted gene therapies have shown dramatic anti-metastasis efficacy and can be quickly moved to clinical trials. The company's iKupffer technology solves multiple obstacles to develop first-in-class immune-cell therapies for desmoplastic GI cancers

AXLR

STAND H26

www.axlr.com

AxLR is a technology transfer acceleration company. Our specialty is helping innovative projects derived from academic research reach maturity and commercialization. We work with the main public-sector research laboratories in France's Mediterranean area in Occitanie, one of the most dynamic locations in Europe, with over 200 laboratories and some 12,000 researchers.

AEPODIA

STAND D21 /2

www.aepodia.com

Aepodia is a solution provider specialised in the early development of drugs and medical devices up to clinical proof-of-concept (from preclinical to Phase 2). Aepodia offers expertise and innovative approaches to its partners to optimise the clinical development programmes of products as well as the management and operational execution of clinical studies carried out in multiple countries. With offices in Belgium and France, Aepodia is a recognised partner for pharma and biotech companies.

ALCEDIAG

STAND E13-11

www.alcediag-alcen.com

Created in 2013, ALCEDIAG is a personalized medicine company specializing in the development of diagnostics tests and clinical biomarkers with a primary focus on mental health and «precision psychiatry». ALCEDIAG has developed different signatures of blood biomarkers based on analysis of RNA editing, an epigenetic mechanism, combined with Artificial Intelligence algorithms. The first product of ALCEDIAG is Edii-B, a blood test to differentiate bipolar depression from unipolar depression.

AQUITAINE SCIENCE TRANSFERT

www.innovations-aquitaine.com

STAND H26

Aquitaine Science Transfert is the Technology Transfer Office for the south west of France, covering 5500 researchers and 135 laboratories. We represent the regional academic research labs: Bordeaux University, INSERM, CNRS, Pau University, Bordeaux Polytechnic Institute... Since our creation in July 2012, we have signed 48 license agreements, patented 285 technologies and created 17 startups. Health, wellness and medical devices represent a key business in which our company is highly involved.

BACHEM AG

STAND E15

www.bachem.com

Bachem is specialized in the process development and manufacturing of peptide-based active pharmaceutical ingredients. A comprehensive catalog of biochemicals and exclusive custom syntheses for research labs complete the service portfolio. Headquartered in Switzerland with subsidiaries in Europe, the US and Asia, the group has a global reach. Bachem shows total commitment to quality, innovation and partnership. Bachem. Pioneering Partner for Peptides.

BIC - BIOMARKER COMMERCIALIZATION
www.biomarker.nu **STAND G10**

The BIC, Biomarker Commercialisation, is a project developing tools to support researchers, TTOs and small companies for a more successful commercialisation of biomarkers inventions. The final tools will be a BIC Master Tool, from discovery to market launch, a Best Practices Handbook based on experiences from TTO in the field, a screening and selection guide for TTOs and a regulatory guideline. Tools will be available in summer 2020. BIC is granted by the Interreg programme Baltic Sea Region.

BIOALTERNATIVES **STAND 21/5**
www.bioalternatives.com

Bioalternatives offers various in silico, in vitro and ex vivo complementary services that are suitable for drug discovery (screening, profiling, safety) and can also provide you with assays for claim substantiation (proof of concept, repositioning, benchmarking). Our main fields of study are healthy and/or pathological skin (e.g. psoriasis, atopic dermatitis, wound healing, fibrosis, etc.), immune-inflammation and more generally pharmacology (signaling, stress, ageing).

BIODEXTRIS **STAND J23**
www.biodextris.com

Bringing Innovation to life, collaborative biologics development for the next generation! We offer a wide range of development services from fermentation process to purification activities as well as the complementary analytical development and testing. Biodextris has big pharma vaccine origins and experience but what makes us an easy choice is our dedicated project management approach with our team of well experienced project managers saving time and effort. Exactly what a CDMO should be!

BIOGENOUEST **STAND D23**
www.biogenouest.org

Biogenouest provide state-of-the-art research facilities to the scientific community in western France. We combine expertise, capability and equipment through a network of technology core facilities. Our team all strive to develop state-of-the-art technologies platforms drawing on a coordinated approach. Our network brings together 35 technology core facilities that deliver hands-on solutions for labs and businesses across: genomics, proteomics, functional exploration, bioimaging structural and metabolic analysis, bioinformatics.

BIOREA **STAND C13**
www.biorea.fr

Do you need tailor-made biomass of your strain (bacteria, yeast, microalgae)? Do you need tailor-made biomass for your DSP projects? Bioréa, subsidiary of Agril Group, relies on its patented fermentation technology for:
- Taylor-made biomass with complete scale-up from lab scale to industrial volumes
- R&D service to adapt your strain & medium to our technology
Should you want to run more R&D trials in your lab, you can also «Cultivate-it-yourself» with our bioreactor equipment.

BIORN **STAND E24**
www.biorn.org

BioRN is the science and industry cluster of the Rhine-Main-Neckar region around Heidelberg, one of Germany's strongest biotech hubs. It is a non-profit network fostering health innovations and serving its members by creating a rich translational ecosystem as well as promoting, representing and connecting the regional innovation stakeholders. One of BioRN's tools to achieve translation of research is HAEP, a scouting service for a tailored matching between innovation seekers and innovators.

BLOCK-T **STAND I20/1**
www.block-t.com

BLOCK-T is a startup incubated at EURASANTÉ since October 2018, whose main activity is the development of preclinical traceability software. Based on our preclinical research experience, BLOCK-T aims to help improve the quality of preclinical laboratory experiments: Our innovation lies in the creation of TracePic, the first Blockchain traceability software dedicated to laboratories, and developed to improve the tracking and traceability of experimental data.

BRAND INSTITUTE **STAND C14**
www.brandinstitute.com

Brand Institute was created on this principle: provide the highest quality name development services, produced and presented by the most experienced professionals, in a timely manner, and at a competitive price. OUR MISSION: To provide best-in-class strategy, name development, trademark screening, market/safety research and visual identity service to our valued, global clientele, delivered by 250+ of the most experienced and forward-thinking branding professionals in our industry.

CANCEROPÔLE PROVENCE-ALPES-CÔTE D'AZUR
www.canceropole-paca.com **STAND E23-13**

The Canceropôle Provence Alpes-Côte d'Azur is a public consortium gathering about 850 scientists and physicians involved in cancer research in the Région Sud of France. It supports research groups by funding their projects chosen via dedicated calls and establishing new technological platforms. It also aims to accelerate the progress towards the anticancer therapies and diagnostic tools of tomorrow by promoting the maturation of projects and the transfer of results to the clinics.

CARNOT FRANCE FUTUR ELEVAGE
www.francefuturelevage.com **STAND G20**

Carnot France Futur Elevage is a French public research network that provides R&D competences to livestock farming sector businesses, including health, nutrition and breeding systems. It brings together actors from agro-veterinary research from INRA and its academic partners with an international visibility and three Agricultural Technical Institutes leaders in the breeding services.

CEMIPAI **STAND E23-16**
www.cemipai.fr

The CEMIPAI is a CNRS-Montpellier University laboratory made up of one of the largest level 3 containment facility in France. Our services support both basic and translational biomedical research on human pathogens for companies and academics. A screening service is available for semi-automated drug or antibody screening against a growing number of viruses. State-of-the-art BLS3 microscopies offer cutting-edge technology for the detection, quantification and analysis of viruses and bacteria.

CENTRE FOR TRANSFER OF BIOMEDICAL TECHNOLOGIES
www.ctbt.cz/en/intro **STAND E22**

Centre for Transfer of Biomedical Technologies was founded in 2012 at the University Hospital Hradec Králové, Czech Republic as a joint commercialization office for researchers of University Hospital Hradec Králové, University of Hradec Králové and Faculty of Military Health Sciences, University of Defense. The mission of CTBT is to protect the intellectual property of all participating institutions, and to transfer the outcomes of R&D to the market and to negotiate and contract research.

CER GROUPE
www.cergroupe.be

STAND I10

CER Groupe is a Belgian Registered Research Center established 40 years ago providing services, products and research in veterinarian, biotech and biomedical areas. Our activities are focused on preclinical, analytical and biomanufacturing fields. We offer fully customized and integrated solutions to our partners, from start-up, spin-offs and early-stage companies to big pharma. These services are performed according to the most appropriate quality standards, from R&D up to GLP and GMP.

CLUBSTER NHL
www.nhl-cluster.com

STAND I20

Clubster NHL – Nutrition, Health, Longevity – is a French competitiveness cluster federating 350 members in the Nutrition, biotechnology and health sectors. We foster collaboration between academia, private companies (start-up, SMEs and large companies), clinicians and final users. Our aim is to help our members to design, develop and finance their innovative products and processes. The activity encompasses the ONE HEALTH concept, close relation between human, animal and plant health.

CZECHINVEST
www.czechinvest.org

STAND H23

CzechInvest, the Investment and Business Development agency of the Ministry of Industry and Trade, works with businesses based in the Czech Republic to support their development and encourages foreign companies to look at the Czech Republic as their partner of choice. Our consultancy services are provided free of charge and cover among others market intelligence including technology scouting as well as strategic and R&D collaboration in strategic sectors including biotechnology, pharmaceuticals

DRUGABILIS
www.drugabilis.com

STAND D21 / 10

DRUGABILIS is an established CRO specialized in pharmaceutical drugability of R&D compounds, including cytotoxic drugs. Our expertise includes API Solid Form Optimization (salts, polymorphs, cocrystals) & Early Formulation, ranging from animal formulation (efficacy, PK, Tox) to early clinical formulation feasibility assessment (oral low soluble, injectable, ocular, dermal, vaginal ...). Our recent relocation to new facilities allowed us increasing our capacities for new projects and clients.

CILCARE
www.cilcare.com

STAND D21 / 6

Cilcare is the world's leading CRO offering preclinical services and consultancy in ear disorders. Based in Montpellier, Boston, and Paris, Cilcare supports pharma, medtech, nutraceutical, and veterinary industries to assess efficacy and safety of drugs, cell and gene-based therapies, medical devices on hearing loss, tinnitus, and otic disorders.

CRYOPDP AN AIR LIQUIDE COMPANY
www.cryopdp.com

STAND C10

For over 25 years, CRYOPDP, an Air Liquide subsidiary, advise his lifescience industry customers for the transport of their temperature and time sensitive products. CRYOPDP design tailor-made solutions to secure the logistic of clinical trials and R&D samples, thanks to a team of logistic experts and all the entities strategically located around the world.

DHUNE
www.dhune.org

STAND G14

The DHUNE center is one of the 7 French Centers of Excellence on Neurodegeneration. Approaching the disease differently, establishing bridges between clinical and pre-clinical research, involving both different hospital clusters and academic research teams, patients, industrialists of the sector, and education, DHUNE aims to achieve discoveries on motor skills, cognition, daily life of patients with neurodegenerative diseases and to obtain faster progress on these diseases.

EATRIS
www.eatris.eu

STAND G14

EATRIS helps you de-risk and add value to your drug, vaccine or diagnostic development programme. We do this by providing fast, tailored access to clinical expertise and cutting-edge enabling technologies available within our 90 academic centres across Europe. Solutions are provided in the fields of advanced therapy medicinal products, biomarkers, imaging and tracing, small molecules and vaccines.

CILOA
www.ciloa.fr

STAND E23-14 / E23-15

CILOA'S CUSTOMIZED EXOSOMES FOR INNOVATIVE THERAPEUTICS. Ciloa is the Pioneer exosome Company with the highest R&D experience on recombinant exosomes. Ciloa innovative platform allows to develop Therapeutic Vectors, Therapeutic Antibodies and Adjuvant- & Virus-Free Vaccines. Ciloa customizes exosomes in vivo to contain i) fully native membrane protein complexes (GPCRs, Kinase Rec., Transporters, Ion Channels, Viral Antigens, ...) embedded in their membrane and ii) any proteins inside their cytosol.

CYNBIOSE
www.cynbiose.com

STAND D21 / 3

Cynbiose is a preclinical CRO specialized in nonhuman primate (NHP) translational models for biomedical research. We provide preclinical services ranging from PK/PD exploratory studies to pharmacological PoC studies in various physiopathological diseases models (Infectious and respiratory diseases, CNS, Rheumatology, Cardiovascular diseases,...). We also provide different proprietary technical platforms and the Immunolead platform for the assessment of immunotherapies and vaccines.

DIM1HEALTH
www.dim1health.com

STAND D25

DIM1HEALTH is a research grant based on three areas – environmental health, human health and animal health – whose close interactions make them inseparable from each other. The "One Health" concept came into being in a context characterized by climate change, worldwide demographic growth, scarcity of natural resources, and shifting health pressures in both human and animal populations.

ER2I INGÉNIERIE
www.er2i.eu

STAND F23

Engineering and general contractor – designer and builder of buildings and complex processes. ER2i engineering is an engineering and contracting company based in Grenoble, Lyon and Paris, which specialize in high standards buildings and structures. We are recognized on both the national and international levels, as a main actor of the construction sector for specific and innovative markets. We are specialized in pharmaceutical and cosmetic industries, medtech and research laboratories.

ERDYN
www.erdyn.com

STAND E12

Erdyn is a pure player of innovation. Erdyn is a leader consulting company specialized in innovation. We support our clients from strategies set up to their operational implementation to sustain growth and competitiveness through innovation.

We offer support for:

- Set up and management of collaborative projects
- Innovation marketing and business development
- Technological and scientific states of the art
- Technology/opportunity scouting

EU-JAPAN CENTRE FOR INDUSTRIAL COOPERATION
www.eu-japan.eu

STAND F11

The EU-Japan Centre for Industrial Cooperation is a unique organisation between the European Commission (DG GROW) and the Japanese Government (METI). The EU-Japan Centre manages matchmaking missions, information seminars and researches, managerial training courses, student placement programmes and other services all designed to help bring European and Japanese businesses together. In October 2020, the Centre will organise a Biotech mission to Japan on the fringes of "BioJapan 2020".

EURASANTÉ
www.eurasante.com

STAND I20

Eurasanté is a development agency dedicated to tech transfer and business development in life sciences sector in Northern France region. Our experienced project managers help researchers, startups and companies with their development projects. To do so, Eurasante provides many services such as real estate, fundraising, recruitment and business development. It also promotes the Eurasante Bio-business Park, which already hosts 8 hospitals, 4 universities, 8 specialised schools and more than 170 companies. It benefits from an exceptional location at the heart of Europe.

EUROBIOMED
www.eurobiomed.org

STAND E23

EUROBIOMED is the catalyst of the health sector in Southern France. EUROBIOMED leads territorial initiatives, provides resources and offers solutions for businesses and research organizations. EUROBIOMED helps them to innovate, finance, develop and achieve their strategic and business objectives to ultimately improve life through innovations in health. EUROBIOMED tops European rankings in all stages of innovation. Together, the + 390 EUROBIOMED members are a driving force in regional development (with 290 projects, representing +1 billion Euros).

EUROFINS CDMO
www.eurofins.cmo/cdm

STAND E14

Eurofins CDMO provides integrated, end-to-end development and manufacturing services for Drug Substance/API and Drug Product manufacturing for biologics and small molecules. We are experts for highly potent compounds, poorly soluble drugs, lyophilisation processes, orphan drugs, paediatric forms... Our services: DS Development, Solid State R&D, Preformulation, Formulation Development, GMP Manufacturing, Clinical Packaging and Logistics, CMC Regulatory Support.

EUROPEAN CENTRE FOR CLINICAL RESEARCH TRAINING
www.eccrt.com

STAND I13

The European Centre for Clinical Research Training (ECCRT) is a professional clinical research training organisation for the pharma, biotech & medical device industries as well as for investigational and academic groups doing clinical trials. We are focusing on the transfer of implementable knowledge for the day-to-day activities of our participants whether being new to the industry, starters on the job, or seasoned professionals.

E-ZYVEC
www.e-zyvec.com

STAND I20/5

We provide an integrated service for design and production of tailor-made DNA vectors. We enable ambitious projects by generating powerful molecular tools in shorter times. We are R&D boosters, we help progress makers! We contribute to the biotechnologies that will make the century greener, safer and more sustainable.

FGK CLINICAL RESEARCH GMBH
www.fgk-cro.com

STAND H21

FGK provides full service for clinical studies to biotech, medical device and pharmaceutical companies. FGK has the right size to handle big international studies as well as small single country studies and can guarantee a personal service to the sponsor. With our 140 highly qualified medical, scientific and regulatory experts, we have all knowledge and experience necessary to succeed in Europe and can guide you through the clinical trial process, from planning and approval to the final report.

FINDMED
www.findmed.fr

STAND H24

FINDMED is a consortium of academic Carnot institutes devoted to human and animal Health. Covering the whole R&D value chain, its role is to support Small Medium-sized Enterprises development by facilitating access to academic research and technological resources. It gathers 7 leading institutes in Health (Vision institute, Institut Pasteur, Institut Curie, ICM, INRA, CALYM, Imagine) and 7 more in chemistry and technology (Chimie Balard Cirimat, I2C, M.I.N.E.S, Smiles, TN@UPSaclay, IPGG, MICA).

GENBIOTECH
www.genbiotech.com

STAND E23-2

Genbiotech, a R&D subsidiary of Laboratoires Genévrier located in Sophia-Antipolis, offers its certified controlled atmosphere zone for rental. Our bioproduction site qualified by AEC partners in 2018. Each of the 7 independent clean rooms (20 to 50 m², Class B, ISO 5), fully equipped, ensures a controlled environment for production. This unique cleanrooms rental offer combines our how-know and both functional and operational flexibility (e.g. integration of specific equipment, rental period...)

GET-INRA TRANSFERT
www.get.genotoul.fr/get-it

STAND H11

GeT-IT (Genomics and Transcriptomics-INRA TRANSFERT) offers a range of services based on innovations from INRA (GeT and LBE-INRA platforms) that meet the expectations and needs of companies in genomic and transcriptomic applications, clinical studies or pilot projects. Our service allows us to offer multi-technology approaches to answer some biological questions of private companies, including sequencing strategy advices (NovaSeq, MiSeq, ONT...), DNA/RNA extraction, data production and bioinformatics/biostatistics analyses. GeT-IT offers a complete range of services to reach the needs of companies in the healthcare, pharmaceutical / cosmetics, biotechnology, agri-food, agricultural, animal and environmental sectors.

GILSON
www.gilson.com

STAND I12

Gilson - a leader in fluidics, purification and sample management - manufactures instrumentation and software that enables our customers to safely purify and accurately manipulate their valuable samples. All our ranges and products have been built upon our knowledge gained from manufacturing reliable equipment for over 50 years. It includes at once automated liquid handling instruments (Prep HPLC, SPE, GPC Clean-up...) and manual liquid handling products as PIPETMAN® pipettes.

HALIODX
www.haliidx.com

STAND D24

HaliDx is an immuno-oncology diagnostic company providing oncologists with diagnostic products and services to guide cancer care and contribute to precision medicine in the era of immuno-oncology. HaliDx executes biomarker studies and companion diagnostic assay development in conformity with regulations and in partnership with biopharmaceutical companies. HaliDx has an experienced team of more than 165 employees, CLIA-certified laboratories and compliant facilities in Europe and in the US.

HCS PHARMA
www.hcs-pharma.com

STAND I20/2

HCS Pharma is a biotech company focused on preclinical in vitro studies, specialized in high content analysis (HCA) and high content screening (HCS). We evaluate the efficacy and safety of your molecules (drug, ingredient, or cosmetic actives) on innovative 2D and 3D cellular models. HCS Pharma owns and sells BIOMIMESYS® technology, a reproducible and physiological surrogate extracellular matrix for 3D cell culture.

HIGH FORCE RESEARCH LTD
www.highforceresearch.com **STAND C12**

HFR is a premier CRO/CDMO company, creating specialist materials to GMP standards and developing synthetic manufacturing processes. With extensive experience of applied chemistry across numerous industry sectors and academia, our materials are used in wide range applications from Pharmaceuticals to Diagnostics, and Smart Materials to Organic Electronics. We operate a hybrid business model combining CRO/CDMO with collaborative research programmes aimed at the development of value added products.

HOLODIAG
www.holodiag.com

STAND J14

Holodiag is your expert CRO dedicated to API solid state, crystallization process and preformulation. Our services include:

- Solid state screenings (polymorph, salt, co-crystal);
- Solid form studies (solubility, dissolution, stability);
- Crystallization process (solid form control, yield/purity, particle engineering, filtration/drying);
- Method development (XRPD, DSC, TGA, DVS, PSD and more).

HPC - COES
www.focus-coe.eu

STAND D12

The HPC Centres of Excellence (CoEs) are EU funded projects supporting the uptake of simulation and numerical modelling in industry in various domains of life sciences. The project CompBioMed is focussed on tools and support for cardiovascular and neuro-musculoskeletal simulation & molecular medicine. The POP project provides performance optimisation & productivity services for academic and industrial codes. These projects offer professional services delivered by the research community itself.

ID2SANTÉ
www.id2sante.fr

STAND E13

ID2Santé is a technology innovation centre operating in the Bretagne region (Western France). It is also the regional representative of the Atlanpole Biotherapies competitiveness cluster. It is in close contact with regional researchers and companies from the health sector and helps forge partnerships to support R&D projects and to develop innovative health products.

IMMUNE INSIGHT **STAND I20/3**
www.immune-insight.com

Immune insight is a CRO which carries ex-vivo and in-vivo preclinical assessment of new active molecules on the immune system in the fields of Cancer, Autoimmune and Inflammatory diseases. Immune Insight has a strong expertise in Treg full analysis but provides also a full range of services including phenotypic, metabolic, functional, recruitment and conversion analysis of several other human immune cells (monocytes, NK, macrophages, B and T cells, Neutrophils...).

IMODE
www.project-imode.eu

STAND E21

The IMODE project is motivated by an unmet need for developing solutions to address societal challenges for improved healthcare, novel and effective medicines for various cardiovascular or digestive diseases, which have inadequate or lack of treatment while maintaining low medical costs. The IMODE project is divided in two main scientific workpackages: -Innovative pharmaceutical formulations and technologies; -Innovative medical devices with improved therapeutical activity based on co-drugs.

INOVA SOFTWARE **STAND D13**
www.inova-software.com

Inova Software accelerates biopharma partnering. Our cloud-based solutions help life science companies manage their opportunities more efficiently. They find all their partnering information in one place, track their deals and alliances easily, and report on their pipeline and activities in seconds. Over 130 life science companies, including 50% of the top 50 pharma companies and many midsize pharma, biotechs and research institutes, already use Inova.

INSERM TRANSFERT **STAND H20**
www.technology-offers.inserm-transfert.com

As a private subsidiary of the French National Institute of the Health and Medical Research (Inserm), Inserm Transfert manages economic and societal value creation and the transfer of knowledge from Inserm research laboratories to companies, contributing to promote human health innovation and long-term technology transfers in line with international best practices.

INSTITUT CARNOT CALYM **STAND H24**
www.calym.org

The CALYM Carnot Institute brings together 15 research teams specialized in lymphoma, first blood cancer. This academic consortium, without international equivalent, aims at accelerating innovation and its transfer in the lymphoma treatment and diagnosis through a unique R&D offering: from the identification of new biological targets to registration clinical trials.

INSTITUT CARNOT CHIMIE BALARD CIRIMAT **STAND H24**
www.carnot-chimie-balard-cirimat.fr

The Chimie Balard Cirimat Carnot Institute provides companies with R&D support in Chemistry, Materials and Processes. We offer innovative solutions to our partners, drawing upon our expertise in green chemistry and processes and in materials with enhanced properties. The comprehensive coverage by our research groups and the access to four state-of-the-art technological platforms allows us to meet any challenge from the energy, health, cosmetics and transport industries.

INSTITUT CARNOT CURIE CANCER
www.techtransfer.institut-curie.org
STAND H24

Composed of a world-renowned research center and a state-of-the-art hospital group, including 3300 researchers, physicians and caregivers, the Carnot Curie Cancer Institute is a leading player in the fight against cancer. Through its Technology Transfer and Industrial Partnerships Office, the Carnot Curie Cancer ensures that Institut Curie and partners' inventions nurture from bench to bedside and receive the greatest chance of actually reaching patients.

INSTITUT CARNOT ICM **STAND H24**
www.icm-institute.org/fr

The ICM Carnot Institute is comprised of a research center, a center for clinical investigation and an incubator for start-ups dedicated to finding solutions for diseases and disorders of the central nervous system. Headquartered in a 22,000 sqm building equipped with the latest technological core facilities, our goal is to promote strong partnerships as a means to accelerate translational research and respond to industry actors' unmet needs.

INSTITUT CARNOT M.I.N.E.S.
www.plateforme-gala.com **STAND H24**

Composed of Armines and 8 engineering schools, the M.I.N.E.S Carnot Institute is built on a multi-disciplinary academic foundation enhanced by a 50-year heritage of providing solutions to meet the needs of the socio-economic players. Truly inspirational for companies seeking innovation, the M.I.N.E.S Carnot Institute draws its strength from its motivation to break down scientific barriers.

INSTITUT CARNOT MICA **STAND H24**
www.carnot-mica.fr

Specialist in functional materials, surfaces and interfaces, the Carnot MICA Institute supports companies in the design and development of their products and services. With his 17 laboratories and technical centers, all experts in materials and innovative solutions, the Carnot MICA Institute offers companies a comprehensive offering, ranging from basic research to industrial applications.

INSTITUT CARNOT PASTEUR MS
STAND H24
www.research.pasteur.fr/fr/program_project/ms-carnot

Institut Carnot Pasteur Microbes & Santé supports research on infectious and chronic diseases, the role of microbiota in health, and on host-pathogen interactions. Its goal is to help industrial stakeholders develop innovative products in the fields of therapeutics, diagnostics, vaccines and technologies for biology. It consists of six research departments (Cell Biology & Infection, Global Health, Microbiology, Parasites and Insect Vectors, Virology, Mycology) and technological platforms.

INSTITUT CARNOT QUALIMENT®
www.qualiment.fr **STAND H24**

Meeting consumer expectations with regards to the sensory and nutritional quality of foods as part of a sustainable food process is a major challenge in terms of innovation. As such, the Qualiment® Carnot Institute implements scientific and technological resources required to support companies in their projects in the field of improvement and development of food products.

INSTITUT CARNOT SMILES **STAND H24**
www.carnot-smiles.fr

The Carnot SMILES is a public research institute which aims at making the most of the power of applied mathematics, through collaborative research, in order to foster innovation within companies. Made up of multi-disciplinary teams, the institute accompanies its industrial partners in their technological challenges regarding bioscience (among other themes): molecular dynamics simulation, growth of cells population modeling, wound healing modeling, protein-protein interaction, metagenomics.

INSTITUT CARNOT STAR **STAND F14**
www.institutcarnotstar.com

Bringing together a multidisciplinary consortium of 8 laboratories and technological platforms in physics, biology, medicine, computer science and engineering, Carnot STAR offers to the industry a set of complementary scientific expertise and know-how to support its innovation projects in the field « Sport, health and well-being ». STAR offers solutions adapted to needs of industry for :

- Research & Development
- Expertise and advice
- Services.

INSTITUT CARNOT TN@UPSACLAY
www.list.cea.fr **STAND H24**

The CEA List, labelled Institut Carnot "Technologies Numériques @UPSAclay" (TN@UPSAclay), conducts research on smart digital systems for industry. Its R&D programs, all with potentially major economic and social implications, focus on the factory of the future, the artificial intelligence and the digital health. By developing cutting-edge technological research, the List helps its industrial partners to enhance their competitiveness through innovation and technology transfer.

INSTITUT CARNOT VOIR ET ENTENDRE
www.institut-vision.org **STAND H24**

The «Voir et Entendre» Carnot Institute represents one of the most important international centers in neurosensory research. This institute is designed as a place of exchange gathering on the same site patients, clinicians, researchers and industrials in order to accelerate innovation in terms of health products and high technology, while bringing solutions to unmet needs of people impaired by pathologies and handicaps affecting visual and hearing systems.

IODA CONSULTING **STAND E23-1**
www.iodaconsulting.fr

IODA, the alliance of financial strategy and scientific expertise. Our cabinet is specialised on innovative companies, with a strong background on all healthcare sectors. We provide consulting services for accounting, tax credit mechanisms and funding. IODA's partners and our teams are fully committed at your sides with smart and accurate solutions to achieve your objectives, at every step of your development, through a win/win & long-term partnership.

IPAZ **STAND D11**
www.ipaz.eu

IP-Patents-Trademarks-Design-Strategy-Contracts-Litigation. IPAZ is one of the leading Intellectual Property firms in France. IPAZ provides IP expertise and have a strong record serving companies, research organizations and project leaders. IPAZ will support you to protect and defend your IP rights and help you in IP agreements and in IP litigations, in France and around the world. Our vision of IP integrates the client company's business strategy to best serve its interests.

IPSIDE
www.ipside.com

STAND D16

For 40 years, IPSIDE has supported innovation and supported its clients in intellectual property consulting. Its experts protect your creations, defend your rights, enhance your projects. Large groups, SMEs, startups or independent inventors, IP is a real strategic issue.

LIFESCIENTIS
www.lifescientis.com

STAND E23-17

LifeScientis develops innovative and sustainable solutions for encapsulation, vectorization and targeted delivery of compounds. In addition, our expertise in toxicological risk assessment enables us to guide our partners in the definition and implementation of a tailored safety strategy for their products. Committed to improving the performance of products and guaranteeing people safety, LifeScientis anticipates the societal and regulatory challenges of the Life Sciences industries.

METAGENOPOLIS
www.mgps.eu

STAND H11

MetaGenoPolis is the INRA center of shotgun metagenomic in human and animal microbiome research. In collaboration with industries, academics and clinics, MGP conceives and implements projects tailored to the partner's need. ISO 9001 certified, the protocols and procedures implemented are constantly kept at the cutting edge of technology. MGP proposes quantitative and functional metagenomic to analyse complex microbiome diversity and interactions between gut bacteria and human cells.

MONTPELLIER FRANCE HEALTH HUB
STAND E23-3
www.montpellier-capital-sante.com/en

Montpellier is a territory for research and innovation, with strong entrepreneurial vitality and a long tradition in health, now set on medicine of the future. A fertilizing environment: presence of leading French research centers, a widely recognized university hospital (CHU), the successful University of Montpellier, the BIC startup incubator ranked 2nd in UBI Global 2018, a site dedicated to companies (Biopôle Euromédecine), the Eurobiomed competitiveness cluster, more than 200 companies...

IQUALIT
www.igualit.com

STAND F12

In an era of digitalization, Big Data and Data Science, data is a major part of every company. For the Life Sciences, data management is critical. Our duty is to go with every company improving their information system, handling, hosting and processing their data processing with quality assurance. Our services are focused on 3 main expertises : Data Compliance, Data Center and Data to Information. Each service is in compliance with Life Sciences regulations and professional recommendations.

LINKSIUM
www.linksium.fr

STAND H26

Linksium selects and reinforces disruptive technologies generated by deep public research results in Grenoble Alps area. All funded projects have valuable intellectual property inside. At a glance, business players can easily discover and scout most promising technologies and startups that may be the next game changers of the market. Linksium funded 157 technologies with 33 M€, fostering to the creation of 36 startups. 30% of its technologies portfolio (licenses or startups) push back scientific boundaries in health field, and specifically for medical devices.

MÉTROPOLE AIX-MARSEILLE PROVENCE
www.ampmetropole.fr

STAND E23

From Basic research to receiving patients, and including medical cosmetology and the expertise from innovative therapies, the metropolis encompasses a very wide scope in the healthcare field. Infectious diseases, immunology, oncology, neurology, innovative therapies : an integrated organization, supported by a very high level training base and supported by leading companies and laboratories and Eurobiomed Cluster. Backed by publicly-funded research, this sector has extensive international connections.

NEURATRIS
www.neuratris.com

STAND G14

Achieve your translational neuroscience projects with NeurATRIS one-stop shop. NeurATRIS is a French research infrastructure accelerating translation of research discoveries into medical innovations for the diagnosis and treatment of neurodegenerative diseases. NeurATRIS gathers a wide range of cutting-edge scientific and clinical expertise, and state-of-the-art platforms (neuroimaging, animal models, aptamers, etc.) covering the entire value chain of translational neuroscience research.

LAXAI LIFE SCIENCES LTD. **STAND J21**
www.laxai.com

LAXAI is a fully integrated contract research and development organization that delivers solutions in early drug discovery, chemical process development, and GMP manufacturing for pharmaceutical, animal health, and agrochemical industries globally. Our focus is on providing highly efficient and well considered scientific solutions at relatively less time and cost compared to industry standards. Our experience, spanning more than a decade, has enabled us to develop deep expertise in custom NCEs.

MEDITOX S.R.O. **STAND D10**
www.meditox.eu

MediTox s.r.o. is GLP-certified CRO focused on pre-clinical R&D (vaccines development, ophthalmic diseases, influenza, osteoarthritis) and comprehensive preclinical and toxicological assessment of human/veterinary drugs, biological, medical devices and food additives in full compliance with GLP standards and international guidelines (EMA, ICH/VICH, OECD, US FDA, ISO 10993). The team is especially strong in preclinical toxicology of non-rodent species (dogs, non-human primates).

MI-MABS **STAND E23-6**
www.mimabs.org

Mi-mAbs is an innovative integrated immunotechnology (a consortium) center designed to accelerate the development of new immunotherapy antibodies (mAbs, ADC, Bi-specifics) against cancer and inflammatory diseases. Open to the best targets of academic and industrial research, MI-mAbs generates antibodies and validates them. MI-mAbs, a multi-disciplinary team, involving experts in hybridoma, in molecular biology, biochemistry, immunochemistry, and in vitro / in vivo immunopharmacology.

NEUROSERVICES-ALLIANCE **STAND E23-5**
www.neuros-services-alliance.com

We're a One-Stop Shop CNS CRO for translational data, providing pharma industries with functional readouts in neuro-pharmacology. We generate data from complementary CNS platforms: in vitro & in vivo CNS Electrophysiology and Behavioral tests. Thanks to our strong college of experts, our functional data from Rodent and Human tissues accelerate CNS and Pain research programs thanks to fast and robust lead selection & optimization, investigation of MOA, and validation of target engagement.

NEURO-SYS
www.neuro-sys.com

STAND I15

Neuro-Sys is a research-intensive innovative CRO company specialized in advanced in vitro models of neurodegenerative diseases and drug development. The company offers disease models and analytical services in the CNS/PNS field such as Alzheimer's and Parkinson's disease, ALS... It is specialized in in vitro screening of neuro active molecules and mode of action research. It also accompanies and advises her clients in the drug development from preclinical trials to the clinical phase.

ONTOFORCE NV
www.ontoforce.com

STAND G12

ONTOFORCE is a data science company, that creates and implements big data fabrics with patented semantic search technologies, enabling linked data at large scale. It will result in smarter enterprise information management systems, ready for global use at multinationals, SME's, research institutes, hospitals, and patient organizations. Our mission is to build the best in class, most used linked data platform to find insights in the continuously growing amounts of data efficiently.

PALM'DATA
www.palm-data.com

STAND E23-10

Founded in September 2018, Palm'Data aims to support lifesciences companies (pharmaceuticals, cosmetics, medical devices) in the organization, protection and use of regulatory data. With 20 years of expertise in data lifecycle management in the lifesciences, we support our clients from the audit phase to employee training to meet GxP requirements whether it is paper data, electronic data, samples or specimens. Palm'Data's Sophia-Antipolis archiving site has obtained GLP compliance from ANSM.

PORTEGHAL ACCELERATOR **STAND D17**
www.porteghal.org

Porteghal Accelerator is a biotechnology, nanotechnology, and life sciences startups' commercialization accelerator as well as an innovation management consulting company based in Iran. Our main mission in Porteghal is to support non-business researchers to form startup teams and to provide commercialization services and seed financing to the startup teams who are looking forward to take the innovation journey & pass the commercialization valley of death. We are a bridge from lab to the market!

NOVA BIOMEDICAL
www.novabio.us

STAND C11

Nova Biomedical develops, manufactures, and sells advanced technology blood testing analyzers. We employ over 1,200 people, have subsidiaries in 8 countries and more than 91 distributors. Nova is one of the 25 largest in vitro diagnostic companies in the world and the largest privately owned in vitro diagnostic company in the US. Nova manufactures a series of BioProfile® automated cell culture analyzers for rapid analysis of key nutrients, metabolites, pH, gases, and cell density/cell viability.

OROXCELL
www.oroxcell.com

STAND D21 / 1

After 15 years as service provider for Life Science Industries, Oroxcell is entering the forthcoming decade with novel assays using validated 3D-Organotypic Human Models based assays, for Efficacy, ADME and Safety, while maintaining its GLP compliance status. Areas of expertise: Pharma, Nutrition Health, Dermato-Cosmetic, Medical Device and chemicals.

PMC ISOCHEM
www.pmcisochem.fr

STAND F20

PMC Isochem offers contract research, development, custom manufacturing, catalogue products and innovative solutions for Pharmaceutical companies worldwide. Drug delivery solutions : TPGS- 1000 NF USP for poorly soluble drug formulation and Polyamino acid based solutions for Nano Encapsulation and Polymer Drug Conjugates. CDMO services: GMP industrial exclusive custom synthesis and provides tailor made services from development to production. 3 FDA audited manufacturing plants. Generic APIs: 20 generic API for US, EU and worldwide market.

PRODECYS
www.prodecys.com

STAND E23-7

Consulting firm dedicated to Project Management, we support companies to optimize their projects around 3 key pillars: Project Management Expertise, Training, Implementation of Project management & collaborative tools. We come from a Pharmaceutical Industry PMO. Our consultants are all experienced in international project management and certified on international project management standards. In a nutshell, Prodecys is a concentrate of complementary skills within an agile structure.

NOVAXIA
www.labo-novaxia.com

STAND D21 / 7

Novaxia is an independent player in histology since 1996. Specialized in Toxicology/Pre-clinical, Pharmacology, Academic Research, Dermo-cosmetics, Novaxia is committed to its customers in terms of quality and deadlines. Our expertise allows our teams to offer you a personalized offer (customized protocols respecting your specifications), a guarantee of conformity (GLP accreditation, 100% control of the slides) as well as additional services such as: the scanning of your slides and IHC.

OUEST VALORISATION **STAND H26**
www.ouest-valorisation.fr

Bringing forward laboratory innovations to innovative products Ouest Valorisation is a Société d'Accélération du Transfert de Technologies or Technology Transfer Acceleration Company – TTO. Our mission is to add value to the results produced by public research laboratories, in Brittany and the Pays de la Loire, and to offer attractive innovation resources to socio-economic actors.

POLE PHARMA
www.polepharma.com

STAND E13

Polepharma is the first pharmaceutical alliance in Europe, covering 3 regions (Centre-Val de Loire, Normandie and Ile de France) that ensures 53% of drug production in France. Its network relies on a team of experts who aim at stimulating industrial and economic development of the pharmaceutical industry with actions that promote competitiveness, innovation, attractiveness and the "Made in France".

**RÉGION SUD PROVENCE-ALPES-
CÔTE D'AZUR** **STAND E23**
www.maregionsud.fr

Priority Health
Sud Region is the 2nd health scientific research center, 2nd french region for innovation patents et clinical trials. Region has one of the heaviest french hospital network, a large variety of research platforms and a strong dynamic in clinical, industrial and academic research. The research laboratories are highly renowned in immuno-oncology with Marseille Immunopole cluster, infectious and tropical diseases with Institut hospitalo-universitaire Méditerranée Infection, rare and orphan diseases and neurosciences.

RÉSEAU SATT
www.satt.fr

STAND H26

SATTs are French private TTOs, shared between several public research organizations, created to develop and commercialize research results to be transformed into innovative products. They evaluate, market and license technology from French Universities and Public Research Organizations. Bringing together professionalism, expertise and financing, SATTs come along the transfer chain according to the needs of industry. By increasing the Technology Readiness Levels, they also participate in reducing company risks.

SATT NORD
www.sattnord.fr

STAND H26

SATT Nord accelerate technology transfer from public research to the market. Satt Nord covers the whole value chain of technology transfer: increasing the awareness of researchers to innovation, sourcing high potential inventions in academic research labs, cofunding private-public collaborations, financing proof of concept and prototyping projects, as well as marketing "ready to industrialize" technologies through licensing out agreements, or creating start-up businesses.

SIMV
www.simv.org

STAND G20

The French association for animal health industry (SIMV) represents 39 companies of:

- Veterinary medicines
- Diagnostics
- Animal health devices and technologies

SMO GROUP
www.smo-group.com

STAND C15

SMO Group is a leading Clinical Trial Logistics service provider in CEE and MENA.

- 24/7 temperature-controlled storage
- End-to-end clinical trial logistics
- Global and local expertise

Services:

- Import & Export of IMP, CTS etc.
- Temperature controlled Storage
- Distribution by own couriers in TVC
- Patient Centricity Services
- Comparator Sourcing

15 YEARS CLINICAL TRIAL LOGISTICS HAS BEEN OUR EXPERTISE!

ROOWIN
www.roowin.com

STAND D21 / 8

Roowin is a privately owned Contract Research Organisation (CRO) headquartered in Riom (Auvergne), France. Its core business being in high value added fine chemistry, Roowin offers a large range of chemical services.

We support our customers and partners to advance their drug candidates from early research phase up to licensing out API in phase II or to the Market for small batches (about 20 kg).

SATT SUD-EST
www.sattse.com

STAND B8

SATT Sud-Est is a key player in regional economic development associated with innovation. Its core business – technology transfer – consists of protecting, developing and licensing the results of research from public laboratories in the South & Corsica Regions to the socio-economic world. Its goal is to help companies acquire reliable innovations that are better suited to the industrial challenges they face.

SKILLCELL
www.skillcell-alcen.com

STAND E23-12

Tests that previously required fully equipped laboratories available in your pocket! Starting with IDIR, the first urine test to screen for insulin-resistance, a condition leading to type 2 diabetes, a world health issue. At the intersection of biochemistry, AI and microfluidics, SkillCell breakthrough innovation offers new perspectives for health, food and environment. SkillCell intelligent tests analyze several biomarkers and are so user-friendly that anyone can use them, anytime and anywhere.

SOLADIS
www.soladis.fr

STAND J22

Soladis is a consulting company specialized in health data, composed of 100 expert resources in France, Switzerland, US and Canada. Supporting life science actors, Soladis provides clinical evaluation services (through the CRO Soladis Clinical Studies) as well as methodological and analytical assistance with biostatistical consulting and Machine Learning / AI development.

S&P BRAIN
www.spbrain.com

STAND C17

The company is an Italian academic spinoff, located in Northern Italy (Piedmont region), that was founded in 2016 by a group of senior academic neuroscientists. It offers preclinical studies spanning from a wide range of behavioral tests to models of neurological injuries and degenerative disorders to cardiovascular, endocrine and metabolic measures to toxicological studies. The company seeks industrial, R&D centers for technical, research cooperation or services agreements.

SCIOMICS GMBH
www.sciomics.de

STAND H22

Sciomics offers high-content analysis services for > 1,000 proteins in a single assay including changes of their post-translational modification status.

Typical applications for the platform are:

- Analysis of pathway activity and disease mechanisms;
- Drug MOA studies;
- Novel drug targets discovery;
- Identification and verification of protein biomarkers.

Our immuno-based assays guarantee robust and reproducible results which can easily be translated into clinical assays.

SMALTIS
www.smaltis.fr

STAND D21 / 9

SMALTIS is a French laboratory expert in microbiology, delivering high added value and personalized technological solutions to support the development of health products, from research to clinical trials. Its fields of expertise are the fight against antibiotic resistance, the exploration of microbiota and the strain engineering for research and bioproduction applications. SMALTIS' strengths lie on flexibility, reactivity and partnership.

SYNCROSOME
www.syncrosome.com

STAND E23-18

Syncrosome offers relevant disease models, cutting-edge techniques, specific Biomarkers and a comprehensive background of physiopathology to assist drug discovery companies in selecting their compounds. Our main activities consist in :

- In vivo Drug Efficacy Studies for: CNS, Cardiometabolism, Gastro and Respiratory
- CNS-PK with a special focus in the study of the Blood Brain Barrier passage and/or Neurotransmitter monitoring.
- Early (PK/PD) on rodents and non-rodents species

SYNEOS HEALTH **STAND E23-8**
www.syneoshealth.com

Syneos Health Translational Science, Sophia-Antipolis, France, provides a suite of integrated scientific capabilities from molecular characterization to lead candidate selection, to biomarker validation and model-based drug development, supporting sponsor's drug development. A team of 80+ scientists with expertise in Biomarkers, Pharmacology, DMPK for General medicine, Oncology, Immuno-Inflammatory conditions works in a 31,500sq Laboratory space, with more than 200 state-of-the-art equipment.

THE MABEXPERTS GROUP: RD-BIOTECH, DIACLONE, SYNABS AND QVQ
www.mabexperts.com **STAND B8**

mAbexperts, a team of 4 companies based on complementary expertise in the field of Antibody Engineering, with a large panel of custom services and products.

RD-BIOTECH: High added value custom services in Immunology, Genetic and Cell Engineering: development and biomanufacturing of plasmid DNA, monoclonal antibodies, recombinant proteins and antibodies (Fab, bispecific, scFv...). Analytical platform for proteins characterization and its FastELISA kits range.

DIACLONE: Centre of excellence in Monoclonal Antibody and Immunoassay development, with an extensive product portfolio of mAbs, ELISA and ELISpot kits (such as its murine and human IFN- ELISpot). Expertise in antibody development (hybridoma and phage display) and bioassays services.

SYNABS: A catalogue of anti-species secondary antibodies (anti-human, mouse, rat, bovine, rabbit,...) and an extensive expertise in the development of monoclonal antibodies in mice, as well as in rats (LOU rats) and guinea pigs using highly innovative technologies.

QVQ: Recognized expertise in the phage display development of antibody fragments (VHH) from llamas. In addition to its services, offers a range of exclusive and high-quality VHHs.

TOULOUSE TECH TRANSFER **STAND H26**
www.toulouse-tech-transfer.com

Toulouse Tech Transfer core business is to invest in technology-maturing programs based on academic research results of the Midi-Pyrénées region, which cover:

- IP and legal management, in order to create more value through patents and know-how;
- Marketing to identify which market mix should be targeted;
- Technical operations to design and finance relevant proof of concept programs to reach an attractive level for businesses.

The objective is to license the matured technologies and products to businesses.

TREMPIN CARNOT I2C **STAND H24**
www.i2c.normandie-univ.fr

The associated Carnot I2C brings together 8 research entities from Normandy on the 2nd territory of the chemical industry in France. With a strong expertise in synthesis, analysis and formulation, I2C capitalizes on this chemistry value chain as a privileged partner to support innovation for the pharmaceuticals, fine chemicals, food, bioresources, cosmetics, energy and environmental sectors industries.

TREMPIN CARNOT IMAGINE
www.institutimagine.org **STAND H24**

Within Necker-Enfants malades Hospital in Paris, Imagine Associated Carnot's brings together a large number of genetic diseases' specialists with the aim to better understand these disorders to better diagnose and treat them. Its patient-centered organization and the close collaboration between clinicians and researchers implement a unique translational model that facilitates research collaborations and the establishment of new therapeutic strategies with the industrial partners.

TREMPIN CARNOT INTERFACES
www.carnot-interfaces.fr **STAND H24**

Carnot INTERFACES brings together 5 laboratories of excellence from SORBONNE UNIVERSITE and offers you its expertise in collaborative research specialized in all digital's areas. In Medtech: biomedical imaging, big data, robotics, AI, IOT, knowledge engineering...

TREMPIN CARNOT IPGG MICROFLUIDIQUE
STAND H24

www.institut-pgg.fr/Presentation-du-Tremplin-Carnot-IPGG_266.html

The Institute Pierre-Gilles de Gennes (IPGG) is an Institute of excellence dedicated to microfluidics. Microfluidic is the science of handling fluids on a micrometric scale. Tremplin Carnot IPGG ambition is to bring "microfluidic revolution" to the service of industry with a proven and high level R&I competencies. Entrepreneurs, professionals and experts, if you are curious to learn more about the potential offered by microfluidic and how to partner with us, come and meet us!

TRINITY COLLEGE DUBLIN
www.tcd.ie/innovation/industry **STAND F22**

Trinity College Dublin is Ireland's highest ranked university. Trinity is seeking industry partners in the areas of biomedical science, bioengineering, ehealth, immunology/inflammation and infection, neuroscience and pharmaceutical science, rare diseases, cancer and ageing. Our researchers want to work on collaborative R&D projects, tackling industry relevant research challenges.

UNIVERSITÉ CÔTE D'AZUR
www.univ-cotedazur.fr **STAND E23-9**

Université Côte d'Azur (UCA) is a recently created cluster of higher education establishments that brings together the major players in education and research on the French Riviera. UCA aims to develop a new 21st-century model for French universities, based on new interactions between disciplines and coordination between research, teaching, and innovation. In 2016, UCA won a prestigious "IDEX" award from the French government, placing it among the top 10 world-class universities in France.

UNIVERSITY OF PARDUBICE
www.amtz.in **STAND J20**

University of Pardubice consists of 7 faculties and provides education in the areas of natural and engineering sciences, social sciences and in the medical and artistic fields. Excellent research teams operate in nanotechnologies, material science, separation techniques, mass spectrometry, lipidomics and metabolomics, photoredox catalysis, organic chemistry and technology, etc. Technology transfer has been carried out on a broad scale, e.g. collaborative projects, applied research, IP licensing.

VILLE DE MARSEILLE **STAND E23**
www.marseille.fr

The Phocaean city has been banking for years on the knowledge economy. It has thus fostered the emergence of eight competitiveness clusters in the fields of health and biotechnology (Marseille is the second largest city in France in terms of scientific research). Higher education and research are the foundation of a development strategy for large modern metropolitan areas based on the knowledge economy. Driven by higher metropolitan employment, the knowledge economy is spreading through innovation and skills training throughout the economic fabric.

XELL AG
www.xell.ag

STAND J15

Xell is an innovative partner for the biotech and pharmaceutical industry, providing efficient solutions in cell culture technology. Xell has developed a range of customized and commercial culture media and feed supplements (CD, AOF) for the most commonly used mammalian cell types. Apart from our media platform we offer analytical services (e.g. our powerful spent media analysis) as well as cell culture and process services to better understand cell behaviour and optimize cultivation processes.

XIMBIO
www.ximbio.com

STAND I24

Ximbio is a non-profit that works to commercialise life science reagents of all kinds at scale. Ximbio is part of Cancer Research UK and works with tech transfer offices globally to find, store, produce, market, sell and license research reagents. Ximbio also works with life science reagent supply companies, as well as pharma companies, to supply high quality reagents for internal research use or onward sale.

XPRESS BIOLOGICS
www.xpress-biologics.com

STAND D15

Xpress Biologics is a Contract Development and Manufacturing Organization (CDMO) specialized in the production of Biologics (proteins, antibody fragments and DNA) for preclinical applications specific to the therapeutic, vaccine and diagnostic markets.

The production scale, from 100 mg to 50 g and the quality of the biologics (R&D and GMP-like grades) are adapted for in vitro and in vivo preclinical validation of the biologics.

YESMYPATENT
www.yesmypatent.com

STAND C16

YesMyPatent is a service of the French Patent Law Firm Touroude & Associates, aiming to democratize patent filling in Europe.

Our offer is unique and based on 2 criteria: the expertise of our 25-collaborators teams, all Patent Attorneys accredited by the INPI and/or the European Patent Office, as well as a modern and efficient digital platform.

ZOETIS
www.zoetis.com

STAND G11

Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 65 years of experience in animal health, Zoetis discovers, develops, manufactures and commercializes veterinary vaccines, medicines and diagnostics, which are complemented by genetic tests, biodevices and a range of services.

ZWICKROELL
www.zwickroell.com/fr-fr/industrie-medicale

STAND D14

ZwickRoell is the world's leading supplier of materials testing machines. Our materials testing machines are used worldwide in R&D and quality assurance in more than 20 industries.

ZwickRoell has stood for reliable test results, excellent service, quality and reliability in materials and components testing.

ZwickRoell has all the tools needed to meet requirements of the medical industry : clean room requirements, DQ IQ OQ qualification, Expanded Traceability, climate chambers, dynamic testing.

WE ARE MARSEILLE

Marseille, city of excellence in medical research



we-are-marseille.com

This image shows a full page of primary-ruled paper. It features multiple sets of horizontal lines designed to guide handwriting. Each set consists of three lines: a solid top line, a dashed middle line, and a solid bottom line. These sets are repeated vertically down the entire page, providing ample space for practicing letter formation and alignment. The paper is otherwise blank, with no margins or additional markings.

PUB METROPOLE MARSEILLE

[illegible][illegible]

SPONSORS

GOLD SPONSORS



SILVER SPONSORS



SPONSORS

BRONZE SPONSORS




CONTRIBUTING SPONSORS



PARTNERS

INSTITUTIONAL PARTNERS

PARTNERS



SUPPORTERS



A unique ecosystem to make healthcare revolution happen in Europe

VISION

From precision engineering to smart connected HealthTech, and from academic research to the clinic, NOBEL is creating an European HealthTech ecosystem, for the convergence of nanomedicine with photonics, robotics, biomaterial, smart systems, eHealth and Textile.

MISSIONS

- ✓ **BUILDING AN ECOSYSTEM:** NOBEL organizes multiple events to create a unique meeting place for all the European HealthTech stakeholders.
- ✓ **SHAPING A STRATEGY:** NOBEL builds a common vision for the future of HealthTech in Europe, integrating the separate roadmaps of emerging medical technologies.
- ✓ **ACCELERATING INNOVATION:** NOBEL manages the HealthTech Translation Advisory Board, a premium service offering tailored support to the selected HealthTech innovations, free-of-charge for beneficiaries.

www.nobel-project.eu

 NOBEL_Project  NOBEL Project

The NOBEL Coordination and Support Action has received funding from the European Union's Horizon 2020 research and innovation programme under the grant agreement no .766492

- ✓ Coordinator: European Technology Platform on Nanomedicine (ETPN).
- ✓ Core Partners: CEA, MedTech Europe, Bioanalytik Muenster, VDI/VDE/IT, TecMinho, Fondazione Don Gnocchi, Tyndall National Institute and Nanobiotix (as a third party).
- ✓ Associated partners: national nanomedicine platforms and other emerging technologies ETPs

PARTNERS

MEDIA PARTNERS



LABIOTECH.eu



FLOOR PLAN & LIST

S A V E T H E D A T E



Biofit FOSTERING
INNOVATION
& TRANSFER

The leading European partnering event
for early-stage deals and investment
rounds in the Life Sciences field

**DECEMBER
1ST & 2ND
2020**

**STRASBOURG
FRANCE**

**9TH
EDITION**

Organisers:



Institutional partners: